

Index to

VOLUME 14 1981

PHARMACOLOGY
BIOCHEMISTRY
AND
BEHAVIOR

CONTENTS

Increases in skin resistance of white rats following scopolamine injection. HORSBURGH, R. J. 1

Hyperactivity in developing rats: Sex differences in 6-hydroxydopamine and amphetamine effects. CON-CANNON, J. T. and M. D. SCHECHTER 5

Substance P, hexapeptide pGlu⁶(SP₆₋₁₁), analgesia and serotonin depletion. MÉSZÁROS, J., B. TAR-CHALSKA, S. GAJEWSKA, P. JANICKI, H. DURIASZ and Z. SZRENIAWSKI 11

Gonadectomy and sex differences in the behavioral responses to amphetamine and apomorphine of rats. SAVAGEAU, M. M. and W. W. BEATTY 17

Extended schedule transfer of ethanol discrimination. SCHECHTER, M. D. 23

Ketamine: Convulsant or anti-convulsant? MYSLOBODSKY, M. S., V. GOLOVCHINSKY and M. MINTZ 27

Cholinergic, dopaminergic, noradrenergic, or glutaminergic stimulation ventral to the anterior septum does not specifically suppress defensive behavior. ALBERT, D. J. 35

Combined effects of alcohol and lithium on body composition in the rat model. WANG, J., J. POLLACK, D. BIRNKRANDT, L. DEMIRIAN, I. GRATTON and R. N. PIERSON, JR. 41

Differential actions of classical and atypical antipsychotic drugs on spontaneous neuronal activity in the amygdaloid complex. REBEC, G. V., K. D. ALLOWAY and T. R. BASHORE 49

Viability and sensorimotor development of mice exposed to prenatal short-term ethanol. FISH, B. S., S. A. RANK, J. R. WILSON and A. C. COLLINS 57

Infusions into the oculomotor nucleus or nerve: A method of estimating the dosage at which transmitter antagonists infused intracranially produce nonspecific blocking of neural activity. ALBERT, D. J. 67

Differentiation of opiate receptors in the brain by the selective development of tolerance. SCHULZ, R., M. WÜSTER and A. HERZ 75

Discriminative stimulus properties of cocaine, norcocaine, and n-allylnorcocaine. BEDFORD, J. A., G. L. NAIL, R. F. BORNE and M. C. WILSON 81

Dopamine depletion by 6-hydroxydopamine prevents conditioned taste aversion induced by methylam-phetamine but not lithium chloride. WAGNER, G. C., R. W. FOLTIN, L. S. SEIDEN and C. R. SCHUSTER 85

The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hal-lucinogenic drugs. YAMAMOTO, T. and S. UEKI 89

The effects of opiate antagonists on the discriminative stimulus properties of ethanol. ALTSHULER, H. L., E. APPLEBAUM and T. S. SHIPPENBERG 97

The effects of pimozide during pairing on the transfer of classical conditioning to an operant discrimina-tion. BENINGER, R. J. and A. G. PHILLIPS 101

Brain aldehyde dehydrogenase activity in rat strains with high and low ethanol preferences. INOUE, K., M. RUSI and K. O. LINDROS 107

BRIEF COMMUNICATIONS

Blockade of endogenous opiates reduces activity in the rat. WALKER, J. M., G. G. BERNTSON, T. S. PAULUCCI and T. C. CHAMPNEY	113
Neurochemical consequences following administration of CNS stimulants to the neonatal rat. WAGNER, G. C., C. R. SCHUSTER and L. S. SEIDEN	117
Interaction among <i>d</i>-amphetamine, scopolamine and genotype in avoidance behavior of rats. SATINDER, K. P.	121
<i>ANNOUNCEMENTS</i>	125

CONTENTS

Facilitated shock-induced aggression after chronic treatment with antidepressant drugs in the rat. MOGILNICKA, E. and B. PRZEWŁOCKA	129
Analgesic tolerance produced by morphine pellets is facilitated by analgesic testing. ADVOKAT, C. . .	133
Environmental modulation of analgesic tolerance induced by morphine pellets. ADVOKAT, C. . .	139
Pineal gland and melatonin influence on chronic alcohol consumption by hamsters. RUDEEN, P. K. and S. K. SYMMES	143
Bombesin inhibits stress-induced eating. MORLEY, J. E. and A. S. LEVINE	149
The string test: An early behavioral change in thiamine deficiency. BARCLAY, L. L., G. E. GIBSON and J. P. BLASS	153
Drug preference and mood in humans: Repeated assessment of <i>d</i> -amphetamine. JOHANSON, C. E. and E. H. UHLENHUTH	159
Genetic differences in tolerance to ethanol: A study in UChA and UChB rats. TAMPIER, L., M. E. QUINTANILLA and J. MARDONES	165
Involvement of caudate nucleus, amygdala or reticular formation in neuroleptic and narcotic catalepsy. DUNSTAN, R., C. L. BROEKKAMP and K. G. LLOYD	169
Selective inhibition by nicotine of shock-induced fighting in the rat. DRISCOLL, P. and K. BAETTIG	175
Correlation between antiavoidance activities of antipsychotic drugs in rats and daily clinical doses. KURIBARA, H. and S. TADOKORO	181
Modification of motor activity, passive avoidance conditioning and evoked potentials by microinjections of strychnine in both caudate nuclei in cats. TELLEZ-VILLAGRA, C., F. VAZQUEZ, P. DE LA MORA and H. BRUST-CARMONA	193
Pimozide attenuates lever pressing for water reinforcement in rats. GERBER, G. J., J. SING and R. A. WISE	201
A silicone delivery system for producing binge and continuous ethanol intoxication in rats. ELLISON, G., S. STAUGAITIS and P. CRANE	207
Discriminative stimulus properties of phenacyclidine and five analogues in the squirrel monkey. BRADY, K. T. and R. L. BALSTER	213
"Conflict" situation based on intracranial self-stimulation behavior and the effect of benzodiazepines. GOMITA, Y. and S. UEKI	219
Impairment of instrumental learning in rats by glutamic acid diethyl ester. FREED, W. J. and R. J. WYATT	223

Ethanol-induced depressions in cerebellar and hippocampal neurons of mice selectively bred for differences in ethanol sensitivity: An electrophysiological study. SORENSEN, S., T. DUNWIDDIE, G. McCLEARN, R. FREEDMAN and B. HOFFER	227
Effects of caffeine administration on food and water consumption under various experimental conditions. MERKEL, A. D., M. J. WAYNER, F. B. JOLICOEUR and R. MINTZ	235
Morphine-like stimulus effects in the monkey: Opioids with antagonist properties. SCHAEFER, G. J. and S. G. HOLTZMAN	241
 <i>BRIEF COMMUNICATIONS</i>	
Effects of chronic naloxone treatment on brain-stimulation reward. PERRY, W., R. U. ESPOSITO and C. KORNETSKY	247
Copulatory behavior and sexual reflexes of male rats treated with naloxone. SACHS, B. D., R. J. VALCOURT and H. C. FLAGG	251
A technique for chronic jugular catheterization in the ferret. FLORCZYK, A. P. and J. E. SCHURIG	255
Brain 5-hydroxytryptamine metabolism after portocaval anastomosis: Relationship with ambulation. TRICK-LEBANK, M. D., D. L. BLOXAM, B. D. KANTAMANENI and G. CURZON ...	259
Spatial aversion conditioning with ethanol. CUNNINGHAM, C. L.	263
 <i>ANNOUNCEMENTS</i>	265

CONTENTS

Rapid acquisition of a two-drug discrimination: Time of day effect upon saline state. SCHECHTER, M. D.	269
The stereotyped behavior syndrome: A new model and proposed therapy. KRYZHANOVSKY, G. N. and M. N. ALIEV	273
Unimpaired quinine metabolism in rats with ventromedial hypothalamic lesions. GUNION, M. W., D. F. BROWN, R. H. PETERS and D. NOVIN	283
DOM and related 2,5-dimethoxy-4-alkylphenylisopropylamines: Behavioral and serotonin receptor properties. GLENNON, R. A., D. L. DOOT and R. YOUNG	287
Antagonism of ethanol-induced decrease in LH by para-chlorophenylalanine: Lack of correlation with altered serotonergic mechanisms. CHAPIN, R. E., G. R. BREESE and R. A. MUELLER	293
Social crowding enhances aversiveness of naloxone in rats. PILCHER, C. W. T. and S. M. JONES ..	299
Behavioral and regional neurochemical sequelae of hippocampal destruction in the rat. BÄR, P. R., W. H. GISPEN and R. L. ISAACSON	305
Beta-adrenergic influence on cardiac dynamics during shock-avoidance in dogs. GRIGNOLO, A., K. C. LIGHT and P. A. OBRIST	313
Time dependent changes in anterograde scopolamine-induced amnesia in rats. MOSS, D. E., J. B. ROGERS, J. A. DEUTSCH and R. R. SALOME	321
Morphine differentially affects ventral tegmental and substantia nigra brain reward thresholds. NAZZARO, J. M., T. F. SEEGER and E. L. GARDNER	325
Effect of diazepam on stress induced changes in brain histamine. MAZURKIEWICZ-KWILECKI, I. M.	333
Lack of specificity of an animal behavior model for hallucinogenic drug action. WHITE, F. J., A. M. HOLOHEAN and J. B. APPEL	339
An analysis of visual object reversal learning in the marmoset after amphetamine and haloperidol. RIDLEY, R. M., T. A. J. HAYSTEAD and H. F. BAKER	345
Human social conversation: Effects of ethanol, secobarbital and chlorpromazine. STITZER, M. L., R. R. GRIFFITHS, G. E. BIGELOW and I. LIEBSON	353
Locomotor activity in morphine-dependent and post-dependent rats. BRADY, L. S. and S. G. HOLTZMAN	361
Phenoxybenzamine and bromocriptine attenuate need for REM sleep in rats. RADULOVACKI, M., W. J. WOJCIK, R. WALOVITCH and M. BRODIE	371
Suppression of alcohol drinking with brain aldehyde dehydrogenase inhibition. SINCLAIR, J. D. and K. O. LINDROS	377

L-5-Hydroxytryptophan-induced drinking in rats: Possible mechanisms for induction. THREATTE, R. M., M. J. FREGLY, T. M. CONNOR and D. C. KIKTA	385
Effects of narcotic abstinence on schedule-controlled behavior in dependent rats. STEINFELS, G. F. and G. A. YOUNG	393
Effect of cocaine and lidocaine on the expression of kindled seizures in the rat. STRIPLING, J. S. and C. HENDRICKS	397
 <i>BRIEF COMMUNICATIONS</i>	
Barbiturate dependence and drug preference. TANG, M., K. AHRENSEN and J. L. FALK	405
Cocaine and seizure protection in mice of varying brain weights. DONOVICK, P. J., R. G. BURRIGHT, R. J. FANELLI, B. SYMCHOWICZ and A. RITZ	409
A microcomputer system for the control of behavioral experiments. CARROLL, M. E., P. A. SANTI and R. L. RUDELL	415
Naloxone suppresses food/water consumption in the deprived rat. FOSTER, J. A., M. MORRISON, S. J. DEAN, M. HILL and H. FRENK	419
The effects of electric shock on responding maintained by cocaine in rhesus monkeys. BERGMAN, J. and C. E. JOHANSON	423
 <i>ANNOUNCEMENTS</i>	427

CONTENTS

Effects of chlorpromazine on escape and avoidance responses: A closer look. SPIRDUSO, W. W., L. D. ABRAHAM and M. D. WOLF	433
Central and peripheral effects of lithium on amphetamine-induced hyperactivity in rats. SMITH, D. F.	439
Activity and catch-up growth in hypothyroid rats. NIKOLETSEAS, M. M.	443
Long-term effects of early iron deficiency on consummatory behavior in the rat. WEINBERG, J., L. P. BRETT, S. LEVINE and P. R. DALLMAN	447
Prenatal undernutrition: Effects on behavior, brain chemistry and neuroanatomy in rats. VILLESAS, R., E. VAN MARTHENS and R. P. HAMMER, JR.	455
The effects of tryptophan and manipulations of serotonergic receptors on tonic immobility in chickens. WALLNAU, L. B., G. D. BORDASH and P. CORSO, JR.	463
Tonic immobility in domestic fowl: Possible interaction of serotonergic and dopaminergic mechanisms. WALLNAU, L. B., G. D. BORDASH and P. CORSO, JR.	469
Subchronic treatment with the tricyclic antidepressant DMI increases isolation-induced fighting in rats. WILLNER, P., A. THEODOROU and A. MONTGOMERY	475
Effects of a high-dose treatment of methamphetamine on caudate dopamine and anorexia in rats. BITTNER, S. E., G. C. WAGNER, T. G. AIGNER and L. S. SEIDEN	481
<i>In vivo</i> effects of two novel alkylating benzodiazepines, irazepine and kenazepine. WILLIAMS, E. F., K. C. RICE, M. MATTSON, S. M. PAUL and P. SKOLNICK	487
Pharmacokinetic study of apomorphine-induced stereotypy in food deprived rats. WATANABE, H., S. NAKANO and N. OGAWA	493
Opiate effects in the amygdala central nucleus on heart rate conditioning in rabbits. GALLAGHER, M., B. S. KAPP, C. L. McNALL and J. P. PASCOE	497
Handling-induced seizures and rotational behavior in the Mongolian gerbil. SCHONFELD, A. R. and S. D. GLICK	507
Metabolic and sympatho-adrenal abnormalities in the obese Zucker rat: Effect of chronic phenoxybenzamine treatment. LEVIN, B. E., K. COMAI and A. C. SULLIVAN	517
Neurotransmitter receptors in brain regions of acrylamide-treated rats. I: Effects of a single exposure to acrylamide. AGRAWAL, A. K., P. K. SETH, R. E. SQUIBB, H. A. TILSON, L. L. UPHOUSE and S. C. BONDY	527
Neurotransmitter receptors in brain regions of acrylamide-treated rats. II: Effects of extended exposure to acrylamide. BONDY, S. C., H. A. TILSON and A. K. AGRAWAL	533
Sustained decrease in fat consumption produced by amphetamine in rats maintained on a dietary self-selection regime. KANAREK, R. B., L. HO and R. G. MEADE	539

Disruption of autoshaped responding to a signal of brain-stimulation reward by neuroleptic drugs. PHILLIPS, A. G., A. C. McDONALD and D. M. WILKIE	543
Morphine antagonists and consummatory behaviors. OSTROWSKI, N. L., N. ROWLAND, T. L. FOLEY, J. L. NELSON and L. D. REID	549
Methadone reduces sexual performance and sexual motivation in the male Syrian golden hamster. MURPHY, M. R.	561
<i>BRIEF COMMUNICATIONS</i>	
Naloxone suppresses feeding and drinking but not wheel running in rats. CAREY, M. P., J. A. ROSS and M. P. ENNS	569
An improved pneumatic syringe for self-administration of drugs by rats. WEEKS, J. R.	573
Opiate dependence following acute injections of morphine and naloxone: The assessment of various with- drawal signs. RITZMANN, R. F.	575
Analgesia following intraventricular administration of 2-deoxy-D-glucose. BODNAR, R. J., K. P. MERRIGAN and M. M. WALLACE	579
<i>ANNOUNCEMENTS</i>	583

CONTENTS

Nicotinamide, inosine and hypoxanthine, putative endogenous ligands of the benzodiazepine receptor, opposite to diazepam are much more effective against kynurenine-induced seizures than against pentylenetetrazol-induced seizures. LAPIN, I. P.	589
Central 5-hydroxytryptamine and the effects of hallucinogens and phenobarbital on operant responding in rats. COMMISSARIS, R. L., W. H. LYNESS, K. E. MOORE and R. H. RECH ..	595
Behavioral effects of temperature sensitive mutations affecting metabolism of cAMP in <i>Drosophila melanogaster</i> . SAVVATEEVA, E. V. and N. G. KAMYSHEV	603
Differential effects of intrahippocampally or systemically applied picrotoxin on memory consolidation in rats. GRECKSCH, G. and H. MATTHIES	613
The effects of <i>d</i> -lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM), pentobarbital and methaqualone on punished responding in control and 5,7-dihydroxytryptamine-treated rats. COMMISSARIS, R. L., W. H. LYNESS and R. H. RECH	617
Effect on morphine on circling behaviour in rats with 6-hydroxydopamine striatal lesions and electrolesions of the raphe nucleus. SLATER, P.	625
The antinociceptive effect of vaginal stimulation in the rat is reduced by naloxone. HILL, R. G. and S. J. AYLIFFE	631
Development of physical dependence on <i>t</i> -butanol in rats: An examination using schedule-induced drinking. GRANT, K. A. and H. H. SAMSON	633
Behavioral alterations induced by formaldehyde-derived tetrahydroisoquinolines. MAKOWSKI, E. C. and L. A. ORDOÑEZ	639
Stress and morphine analgesia: Alterations following <i>p</i> -chlorophenylalanine. BODNAR, R. J., J. H. KORDOWER, M. M. WALLACE and H. TAMIR	645
Long-term thermoregulatory changes following perinatal methadone exposure in rats. THOMPSON, C. I. and I. S. ZAGON	653
Tolerance to anorectic drugs: Pharmacological or artifactual. LEVITSKY, D. A., B. J. STRUPP and J. LUPOLI	661
The effect of <i>para</i> -chlorophenylalanine and scopolamine on passive avoidance in chicks. MATTINGLY, B. A. and J. F. ZOLMAN	669
Cross tolerance between morphine and the long-term analgesic reaction to inescapable shock. DRUGAN, R. C., J. W. GRAU, S. F. MAIER, J. MADDEN, IV and J. D. BARCHAS ...	677
Caffeine discrimination in the rat. MODROW, H. E., F. A. HOLLOWAY and J. M. CARNEY	683
A simple, reliable method for predicting the physical dependence liability of narcotic antagonist analgesics in the rat. HOWES, J. F.	689

On the neuropharmacology of harmane and other β -carbolines. MÜLLER, W. E., K. J. FEHSKE, H. O. BORBE, U. WOLLERT, C. NANZ and H. ROMMELSPACHER	693
The mechanism of the lipolytic action of theophylline in fat cells. MIYOSHI, Y., K. UCHIDA, E. TAKEDA-HARA, K. NAGAI and H. OKUDA	701
Dispensability of spinal monoaminergic systems in mediating the lordosis reflex of the female rat. KOW, L.-M., C. M. PADEN and D. W. PFAFF	707
Reversal of guanethidine- and diethyldithiocarbamate-induced amnesia by peripherally-administered catecholamines. WALSH, T. J. and T. PALFAI	713
Mechanism of stress-induced subsensitivity to norepinephrine. STONE, E. A.	719
The effects of cocaine free extracts of the coca leaf on food consumption and locomotor activity. BEDFORD, J. A., M. C. WILSON, H. N. ELSOHLY, C. ELLIOTT, G. COTTAM and C. E. TURNER	725
Regional responses of rat brain noradrenergic neurones to acute intense stress. NAKAGAWA, R., M. TANAKA, Y. KOHNO, Y. NODA and N. NAGASAKI	729
Neurotransmitter-receptor binding in various brain regions in ethanol-dependent rats. HUNT, W. A. and T. K. DALTON	733

BRIEF COMMUNICATIONS

Different effects of apomorphine on locomotor activity in C57BL/6 and DBA/2 mice. SANSONE, M., M. AMMASSARI-TEULE, P. RENZI and A. OLIVERIO	741
Δ -9-Tetrahydrocannabinol stimulates receptive and proceptive sexual behaviors in female hamsters. TURLEY, W. A., JR. and O. R. FLOODY	745
Effects of naloxone on corticosterone response to stress. TAPP, W. N., J. C. MITTLER and B. H. NATELSON	749
Stereotypy and striatal dopamine receptor changes with l- α -acetylmethadol (LAAM). LANGLEY, A. E., J. KIRLANGITIS and T. LEHMAN	753
The role of hot plate and general environmental stimuli in morphine analgesic tolerance. BARDO, M. T., P. J. WELLMAN and R. A. HUGHES	757

ABSTRACTS

Fifth Annual Conference on Alcoholism. February 19-20, 1981.	761
---	-----

<i>ANNOUNCEMENTS</i>	767
----------------------------	-----

CONTENTS

Brain serotonin metabolism in hibernation. POPOVA, N. K. and N. N. VOITENKO	773
The effect of post-conditioning exposure to morphine on the retention of a morphine-induced conditioned taste aversion. JACOBS, W. J., D. A. ZELLNER, V. M. LoLORDO and A. L. RILEY	779
Perception of odors of simple pyrazines by young and elderly subjects: A multidimensional analysis. SCHIFFMAN, S. S. and J. C. LEFFINGWELL	787
Effects of anorectic drugs and prior feeding on food-rewarded runway behavior. THURLBY, P. L. and R. SAMANIN	799
Behavioral effects of thebaine in the rhesus monkey. WOODS, J. H., C. R. SCHUSTER and C. R. HARTEL	805
Sleep-inducing effects of three hypnotics in a new model of insomnia in rats. HALPERIN, J. M., D. MILLER and L. C. IORIO	811
Behavioral assessment of norepinephrine and serotonin function and interaction in the hippocampal formation. GAGE, F. H. and J. E. SPRINGER	815
Effects of nortriptyline treatment on learned helplessness in the rat. TELNER, J. I. and R. L. SINGHAL	823
Chronic methylxanthine treatment in rats: A comparison of Wistar and Fischer 344 strains. LLOYD, H. G. E. and T. W. STONE	827
Quipazine-induced behavior in neonatal rat pups. SPEAR, L. P. and L. A. RISTINE	831
A rapid method to evaluate acute ethanol intoxication in mice. BLUM, K., S. F. ELSTON, H. SCHWERTNER, L. DeLALLO and A. H. BRIGGS	835
An endogenous ligand to the benzodiazepine receptor: Preliminary evaluation of its bioactivity. DAVIS, L. G., H. McINTOSH and D. REKER	839
An analog of ACTH/MSH ₄₋₉₉ , ORG-2766, reduces permeability of the blood-brain barrier. GOLDMAN, H. and S. MURPHY	845
A new approach to the role of noradrenaline in learning: Problem-solving in the marmoset after α -noradrenergic receptor blockade. RIDLEY, R. M., T. A. J. HAYSTEAD, H. F. BAKER and T. J. CROW	849
Schedule induced ethanol polydipsia in psychogenetically selected lines of rats. MARTIN, J. R. and K. BAETTIG	857
Uptake of [³ H]colchicine into brain and liver of mouse, rat, and chick. BENNETT, E. L., M. H. ALBERTI and J. F. FLOOD	863
A precision drinking device for rats tested with water, etonitazene, and ethanol. BEARDSLEY, P. M. and R. A. MEISCH	871

The effects of lead, d-amphetamine, and time of day on activity levels in the mouse. DOLINSKY, Z., E. FINK, R. G. BURRIGHT and P. J. DONOVICK	877
Opiate antagonists and sexual behavior in female hamsters. OSTROWSKI, N. L., R. G. NOBLE and L. D. REID	881
Peripheral conversion of <i>l</i> -5-hydroxytryptophan to serotonin induces drinking in rats. KIKTA, D. C., R. M. THREATTE, C. C. BARNEY, M. J. FREGLY and J. E. GREENLEAF ...	889
Effects of serotonin and <i>l</i> -5-hydroxytryptophan on plasma renin activity in rats. BARNEY, C. C., R. M. THREATTE, D. C. KIKTA and M. J. FREGLY	895
 <i>BRIEF COMMUNICATIONS</i>	
Cardiovascular and behavioral changes after ICV infusion of TRH in the conscious goat. ERIKSSON, L. and A. GORDIN	901
The effects of <i>dl</i> -cathinone in a gustatory avoidance paradigm. FOLTIN, R. W. and C. R. SCHUSTER	907
Modifications of brain steroidogenesis and plasma steroids after <i>p</i> -chlorophenylalanine-methyl-ester treatment in male rats and rabbits. FARABOLLINI, F., C. LUPO DI PRISCO and F. DESSI-FULGHERI	911
The behavioral effects of hallucinogens in rats following 5,7-dihydroxytryptamine administration into the medial forebrain bundle. COMMISSARIS, R. L., D. J. MOKLER, W. H. LYNESS, K. E. MOORE and R. H. RECH	915
Intraventricular N-acetyl-L-glutamate induces retrograde amnesia in chicks. DAVIS, J. L., A. CHERKIN and M. D. HEWITT	919
<i>INDEX TO VOLUME 14</i>	921
<i>ANNOUNCEMENTS</i>	965

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 14, 1981

SUBJECT INDEX

- Abnormal behavior
 - p-chlorophenylalanine, 89
 - 2,5-dimethoxy-4-methylamphetamine, 89
 - head twitch, 89
 - lesions, 89
 - locomotion, 89
 - LSD, 89
 - mescaline, 89
 - methysergide, 89
 - raphe nucleus, 89
 - serotonin, 89
- Abortive groom
 - animal models, 339
 - cat, 339
 - hallucinogens, 339
 - limb-flick, 339
- Abstinence
 - LAAM, 393
 - morphine, 393
 - schedule-controlled behavior, 393
- Abuse liability
 - amphetamine, 159
 - drug preference, 159
 - human, 159
 - POMS, 159
 - subjective effects, 159
- Aceperone
 - discrimination learning, 849
 - marmoset, 849
 - norepinephrine, 849
- Acetaldehyde
 - aldehyde dehydrogenase, 107, 377
 - calcium carbimide, 377
 - cyanamide, 377
 - drinking, 107
 - ethanol, 107, 377
 - genetics, 107
 - 4-methylpyrazole, 377
 - preference, 107
- N-Acetyl-L-glutamate
 - amnesia, 919
 - chicken, 919
 - glutamate, 919
 - proline, 919
- Acetylcholine
 - aggression, 35
 - defensiveness, 35
 - dopamine, 35
 - glutamate, 35
 - hyperreactivity, 35
 - norepinephrine, 35
 - septum, 35
- Acrylamide
 - dopamine, 533
 - neurotransmitters, 527, 533
 - receptors, 527, 533
- ACTH/MSH
 - blood-brain barrier, 845
 - ORG-2766, 845
 - permeability, 845
 - regional cerebral blood flow, 845
- Activity
 - amphetamine, 5, 877
 - animal models, 877
 - cardiovascular effects, 901
 - coca, 725
 - cocaine, 725
 - development, 5
 - dopamine, 5
 - drinking, 569
 - eating, 443, 569, 725
 - food restriction, 443
 - goat, 901
 - 6-hydroxydopamine, 5
 - hyperactivity, 877
 - hypothyroidism, 443
 - intraventricular administration, 901
 - lead, 877
 - light-dark cycle, 877
 - naloxone, 569
 - sex differences, 5
 - skeletal growth, 443
 - TRH, 901
- Adenylate cyclase
 - norepinephrine, 719
 - phosphodiesterase, 719
 - receptors, 719
 - stress, 719
 - subsensitivity, 719
- Adjunctive behavior
 - drug preference, 405
 - phenobarbital, 405
 - physical dependence, 405
 - schedule-induced behavior, 405
 - withdrawal, 405
- Affiliative behavior
 - effects of amphetamine, s103
- Aggression
 - acetylcholine, 35
 - amitriptyline, 129
 - chronic treatment, 475
 - defensiveness, 35
 - desmethylimipramine, 475
 - dopamine, 35

- glutamate, 35
- hyperreactivity, 35
- imipramine, 129
- iprindole, 129
- isolation-induced fighting, 475
- mianserin, 129
- nicotine, 175
- norepinephrine, 35
- septum, 35
- shock thresholds, 175
- Aging
 - multidimensional scaling, 787
 - odor, 787
 - pyrazines, 787
- Agonistic behavior
 - effects of amphetamine, s103
- Alcohol
 - aggressive behavior in fish, s79
- Alcohol congeners
 - aggressive behavior in fish, s79
- Aldehyde dehydrogenase
 - acetaldehyde, 107, 377
 - calcium carbimide, 377
 - cyanamide, 377
 - drinking, 107
 - ethanol, 107, 377
 - genetics, 107
 - 4-methylpyrazole, 377
 - preference, 107
- 4-Alkyl-2,5-dimethoxyamphetamines
 - 4-alkyl-2,5-dimethoxyphenylisopropylamines, 287
 - discriminative stimulus, 287
 - DOET, 287
 - DOM, 287
 - 5-methoxy-N,N-dimethyltryptamine, 287
 - receptors, 287
 - serotonin, 287
- 4-Alkyl-2,5-dimethoxyphenylisopropylamines
 - 4-alkyl-2,5-dimethoxyamphetamines, 287
 - discriminative stimulus, 287
 - DOET, 287
 - DOM, 287
 - 5-methoxy-N,N-dimethyltryptamine, 287
 - receptors, 287
 - serotonin, 287
- N-Allylnorcocaine
 - cocaine, 81
 - discriminative stimulus, 81
 - norcocaine, 81
- Ambulation
 - 5-hydroxyindoleacetic acid, 259
 - non-esterified fatty acid, 259
 - portocaval anastomosis, 259
 - serotonin, 259
- Amitriptyline
 - aggression, 129
 - imipramine, 129
 - iprindole, 129
 - mianserin, 129
- Amnesia
 - N-acetyl-L-glutamate, 919
 - catecholamines, 713
 - chicken, 919
 - cholinergic mechanisms, 321
 - diethyldithiocarbamate, 713
 - glutamate, 919
 - guanethidine, 713
 - memory, 321, 713
 - passive avoidance, 713
 - physostigmine, 321
 - proline, 919
 - scopolamine, 321
- cAMP
 - cyclic nucleotide phosphodiesterase, 603
 - Drosophila melanogaster*, 603
 - isolation-induced fighting, s7
 - learning, 603
 - locomotor activity, 603
 - mouse-killing, s7
 - shock-induced fighting, s7
 - temperature-sensitive mutants, 603
 - x-chromosome, 603
- Amphetamine
 - abuse liability, 159
 - activity, 5, 877
 - affiliative behavior, s103
 - agonistic behavior, s103
 - amygdala, 49
 - animal models, 877
 - anorexia, 539
 - apomorphine, 17
 - avoidance behavior, 121
 - body weight regulation, 661
 - caloric intake, 539
 - carbohydrate, 539
 - catecholamine depletion, 117
 - clozapine, 49
 - CS modality, 121
 - development, 5
 - dietary self-selection, 539
 - dopamine, 5
 - drug discrimination, 269
 - drug preference, 159
 - eating, 661
 - extended schedule of responding, 269
 - fat, 539
 - fenfluramine, 661
 - genetics, 121
 - gonadectomy, 17
 - haloperidol, 49, 345
 - human, 159
 - 6-hydroxydopamine, 5
 - hyperactivity, 877
 - intracerebroventricular injection, 439
 - lead, 877
 - light-dark cycle, 877
 - lithium, 439
 - locomotor activity, 17, 439
 - methylamphetamine, 117
 - methylphenidate, 117
 - neonatal, 117
 - pentobarbital, 269
 - POMS, 159
 - primate, 345
 - protein, 539
 - reversal learning, 345
 - scopolamine, 121
 - sex differences, 5, 17
 - stereotyped behavior, 17
 - subjective effects, 159
 - tolerance, 661
 - unit activity, 49
- Amygdala
 - amphetamine, 49
 - catalepsy, 169
 - caudate nucleus, 169
 - clozapine, 49
 - cocaine, 397
 - haloperidol, 49, 169
 - kindling, 397
 - lidocaine, 397
 - morphine, 169
 - olfactory bulb, 397
 - prepyriform cortex, 397
 - reticular formation, 169
 - seizures, 397
 - unit activity, 49
- Amygdala central nucleus
 - heart rate conditioning, 497
 - opiates, 497

- rabbit, 497
- receptors, 497
- Analgesia
 - catatonia, 75
 - p-chlorophenylalanine, 11, 645
 - cold-water swims, 645
 - cross-tolerance, 75
 - 2-deoxy-D-glucose, 579, 645
 - environmental stimuli, 757
 - pGlu⁶(SP₆₋₁₁), 11
 - hot plate, 757
 - inescapable footshock, 645
 - intraventricular administration, 579
 - lesions, 11
 - morphine, 133, 139, 645, 757
 - opiates, 75
 - pain, 579, 645
 - raphe nucleus, 11
 - receptors, 75
 - serotonin, 11
 - species differences, 11
 - substance P, 11
 - tail flick, 133, 139
 - tolerance, 75, 133, 139, 757
- Angiotensin
 - 2-deoxyglucose, 549
 - drinking, 549
 - eating, 549
 - insulin, 549
 - opiates, 549
 - opiate antagonists, 549
 - polyethylene glycol, 549
 - tail-pinch, 549
- Animal models
 - abortive groom, 339
 - activity, 877
 - amphetamine, 877
 - cat, 339
 - hallucinogens, 339
 - hyperactivity, 877
 - lead, 877
 - light-dark cycle, 877
 - limb-flick, 339
- Anorectics
 - anorexia, 799
 - eating, 799
 - runway behavior, 799
- Anorexia
 - amphetamine, 539
 - anorectics, 799
 - caloric intake, 539
 - carbohydrate, 539
 - caudate nucleus, 481
 - dietary self-selection, 539
 - dopamine, 481
 - eating, 799
 - fat, 539
 - methamphetamine, 481
 - protein, 539
 - runway behavior, 799
 - tolerance, 481
- Anticholinergic
 - scopolamine, 1
 - skin resistance, 1
- Anticonvulsants
 - rotation, 507
 - seizures, 507
- Antidepressants
 - aggressiveness in mice, 533
- Antinociception
 - naloxone, 631
 - vaginal stimulation, 631
- Antipsychotic drugs
 - discriminated avoidance, 181
 - Sidman avoidance, 181
- Apomorphine
 - amphetamine, 17
 - dopamine, 753
 - food deprivation, 493
 - genetics, 741
 - gonadectomy, 17
 - LAAM, 753
 - locomotor activity, 17, 741
 - opiates, 753
 - pharmacokinetics, 493
 - receptors, 753
 - sex differences, 17
 - stereotyped behavior, 17, 493, 753
- Apparatus
 - improved pneumatic syringe for self-administration of drugs by rats, 573
 - microcomputer system for the control of behavioral experiments, 415
 - precision drinking device for rats tested with water, etonitazene, and ethanol, 871
 - silicone delivery system for producing binge and continuous ethanol intoxication in rats, 207
- Approach-avoidance conflict
 - caloric intake, 447
 - consummatory behavior, 447
 - iron deficiency, 447
 - pituitary-adrenal system, 447
 - taste aversion, 447
- Aspartate
 - atropine, 67
 - carbachol, 67
 - glutamate, 67
 - haloperidol, 67
 - intracranial injection, 67
 - lidocaine, 67
 - oculomotor nucleus, 67
 - phentolamine, 67
 - propranolol, 67
 - tolazocine, 67
- Atropine
 - aspartate, 67
 - carbachol, 67
 - glutamate, 67
 - haloperidol, 67
 - intracranial injection, 67
 - lidocaine, 67
 - oculomotor nucleus, 67
 - phentolamine, 67
 - propranolol, 67
 - tolazocine, 67
- Autoshaping
 - extinction, 543
 - haloperidol, 543
 - Pavlovian conditioning, 543
 - pimozide, 543
 - stimulation, 543
- Avoidance behavior
 - amphetamine, 121
 - CS modality, 121
 - genetics, 121
 - intraventricular injections, 639
 - locomotor activity, 639
 - scopolamine, 121
 - tetrahydroisoquinolines, 639
- Axonal transport
 - colchicine, 863
 - memory, 863
 - species differences, 863
 - tubulin, 863
 - uptake, 863
- BASIC
 - microcomputer, 415
 - operant research, 415

- Behavioral activation
 - development, 831
 - mouthng behavior, 831
 - neonatal exposure, 831
 - quipazine, 831
 - serotonin, 831
- Behavioral inhibition
 - dendrites, 455
 - DNA, 455
 - learning, 455
 - protein, 455
- Behavioral reactivity
 - hippocampus, 815
 - norepinephrine, 815
 - serotonin, 815
- Behavioral teratology
 - body weight, 653
 - cating, 653
 - methadone, 653
 - perinatal exposure, 653
 - thermoregulation, 653
- Benzodiazepine
 - bioactivity, 839
 - β -carbolines, 693
 - conflict situation, 219
 - diazepam, 839
 - dopamine, 693
 - endogenous ligand, 693, 839
 - harmane, 693
 - hypothalamus, 219
 - irazepine, 487
 - kenazepine, 487
 - muscarinic, 693
 - pentylentetrazol, 487
 - peptide, 839
 - receptors, 487, 693
 - self-stimulation, 219
 - serotonin, 693
 - specificity, 693
- Benzodiazepine derivatives
 - modification of predatory behavior, s43
- Binge vs continuous drug regimen
 - ethanol, 207
 - intoxication, 207
 - silicone delivery system, 207
 - withdrawal, 207
- Bioactivity
 - benzodiazepines, 839
 - diazepam, 839
 - endogenous ligand, 839
 - peptide, 839
- Blood-brain barrier
 - ACTH/MSH, 845
 - ORG-2766, 845
 - permeability, 845
 - regional cerebral blood flow, 845
- Blood pressure
 - cardiac output, 313
 - decarboxylase inhibitors, 895
 - dobutamine, 313
 - heart rate, 313, 895
 - left ventricular dP/dt, 313
 - practolol, 313
 - renin, 895
 - serotonin, 895
 - stress, 313
 - temperature, 895
- Blood sampling
 - ferret, 255
 - intravenous drug administration, 255
 - jugular catheter, 255
- Body weight
 - behavioral teratology, 653
 - eating, 653
 - ethanol, 857
 - methadone, 653
 - perinatal exposure, 653
 - schedule induced polydipsia, 857
 - sex differences, 857
 - strain differences, 857
 - thermoregulation, 653
- Body weight regulation
 - amphetamine, 661
 - eating, 661
 - fenfluramine, 661
 - tolerance, 661
- Bombesin
 - eating, 149
 - glucose, 149
 - neurotensin, 149
 - satiety, 149
 - tail pinch, 149
- Bone sodium
 - ethanol, 41
 - extracellular water, 41
 - intracellular sodium, 41
 - lithium, 41
- Brain
 - amygdala, 49, 169, 397, 729
 - amygdala central nucleus, 497
 - basal ganglia, 729
 - caudate nucleus, 169, 193, 273, 305, 481
 - cerebellum, 227
 - cerebral cortex, 729
 - hippocampus, 227, 305, 613, 729, 815
 - hypothalamus, 219, 729, 910
 - lateral geniculate, 193
 - medial forebrain bundle, 915
 - neocortex, 305
 - nucleus accumbens, 305
 - occipital cortex, 193
 - oculomotor nucleus, 67
 - olfactory bulb, 397
 - pineal gland, 143
 - pituitary, 447
 - prepyriform cortex, 397
 - raphe nucleus, 11, 89, 625
 - reticular formation, 169
 - septum, 35
 - substantia nigra, 325
 - ventral tegmentum, 325
 - ventromedial hypothalamus, 283
- Brain weight
 - cocaine, 409
 - seizure susceptibility, 409
- Bromocriptine
 - phenoxybenzamine, 371
 - REM sleep, 371
- t-Butanol
 - drinking, 633
 - ethanol, 633
 - physical dependence, 633
 - schedule-induced behavior, 633
- Caffeine
 - drinking, 235
 - drug discrimination, 683
 - eating, 235
 - operant behavior, 683
- Calcium carbimide
 - acetaldehyde, 377
 - aldehyde dehydrogenase, 377
 - cyanamide, 377
 - ethanol, 377
 - 4-methylpyrazole, 377
- Caloric intake
 - amphetamine, 539
 - anorexia, 539
 - approach-avoidance conflict, 447

- carbohydrate, 539
- consummatory behavior, 447
- dietary self-selection, 539
- fat, 539
- iron deficiency, 447
- pituitary-adrenal system, 447
- protein, 539
- taste aversion, 447
- Carbachol
 - aspartate, 67
 - atropine, 67
 - glutamate, 67
 - haloperidol, 67
 - intracranial injection, 67
 - lidocaine, 67
 - oculomotor nucleus, 67
 - phentolamine, 67
 - propranolol, 67
 - tolazocine, 67
- Carbohydrate
 - amphetamine, 539
 - anorexia, 539
 - caloric intake, 539
 - dietary self-selection, 539
 - fat, 539
 - protein, 539
- β -Carbolines
 - benzodiazepine, 693
 - dopamine, 693
 - endogenous ligand, 693
 - harmane, 693
 - muscarinic, 693
 - receptors, 693
 - serotonin, 693
 - specificity, 693
- Cardiac output
 - blood pressure, 313
 - dobutamine, 313
 - heart rate, 313
 - left ventricular dP/dt, 313
 - practolol, 313
 - stress, 313
- Cardiovascular effects
 - activity, 901
 - goat, 901
 - intraventricular administration, 901
 - TRH, 901
- Castration
 - ethanol, 293
 - LH, 293
 - PCPA, 293
 - serotonin, 293
- Cat
 - abortive groom, 339
 - animal models, 339
 - drinking, 419
 - eating, 419
 - food deprivation, 419
 - hallucinogens, 339
 - limb-flick, 339
 - naloxone, 419
 - water deprivation, 419
- Catalepsy
 - amygdala, 169
 - caudate nucleus, 169
 - chicken, 469
 - dopamine, 469
 - haloperidol, 169
 - morphine, 169
 - reticular formation, 169
 - serotonin, 469
 - tonic immobility, 469
 - tryptophan, 469
- Catatonia
 - analgesia, 75
- cross-tolerance, 75
 - opiates, 75
 - receptors, 75
 - tolerance, 75
- Catecholamine depletion
 - amphetamine, 117
 - methylamphetamine, 117
 - methylphenidate, 117
 - neonatal, 117
- Catecholamines
 - amnesia, 713
 - diethyldithiocarbamate, 713
 - guanethidine, 713
 - memory, 713
 - passive avoidance, 713
- Cathinone
 - khat, 907
 - taste aversion, 907
- Caudate nucleus
 - amygdala, 169
 - anorexia, 481
 - catalepsy, 169
 - combined specific therapy, 273
 - determinant structure, 273
 - diazepam, 273
 - dopamine, 481
 - evoked potentials, 193
 - excessive grooming, 305
 - GABA, 273
 - haloperidol, 169, 273
 - hippocampal damage, 305
 - lateral geniculate, 193
 - lithium, 273
 - membrane phosphorylation, 305
 - methamphetamine, 481
 - morphine, 169
 - neocortex, 305
 - nucleus accumbens, 305
 - occipital cortex, 193
 - passive avoidance, 193
 - reticular formation, 169
 - stereotypy, 273
 - strychnine, 193
 - tolerance, 481
- Central excitatory processes
 - glutamic acid diethyl ester, 223
 - instrumental learning, 223
- Cerebellum
 - electrophysiology, 227
 - ethanol, 227
 - genetics, 227
 - hippocampus, 227
 - sleep time, 227
- Chicken
 - N-acetyl-L-glutamate, 919
 - amnesia, 919
 - catalepsy, 469
 - p-chlorophenylalanine, 669
 - dopamine, 469
 - glutamate, 919
 - passive avoidance, 669
 - proline, 919
 - raphe model, 463
 - scopolamine, 669
 - serotonin, 463, 469
 - tonic immobility, 463, 469
 - tryptophan, 463, 469
- p-Chlorophenylalanine
 - abnormal behavior, 89
 - analgesia, 11, 645
 - chicken, 669
 - cold-water swims, 645
 - 2-deoxy-D-glucose, 645
 - 2,5-dimethoxy-4-methylamphetamine, 89
 - pGlu⁶(SP₆₋₁₁), 11

- head twitch, 89
- hypothalamus, 910
- inescapable foot shock, 645
- lesions, 11, 89
- locomotion, 89
- LSD, 89
- mescaline, 89
- methysergide, 85
- morphine, 645
- pain, 645
- passive avoidance, 669
- raphe nucleus, 11, 85
- scopolamine, 669
- serotonin, 11, 85, 911
- species differences, 11
- steroidogenesis, 910
- substance P, 11
- Chlorpromazine
 - conditioned avoidance, 433
 - dopamine, 433
 - ethanol, 353
 - human, 353
 - movement initiation, 433
 - secobarbital, 353
 - social interaction, 353
 - speech, 353
 - subjective reports, 353
- Cholinergic mechanisms
 - amnesia, 321
 - memory, 321
 - physostigmine, 321
 - scopolamine, 321
- Chronic treatment
 - aggression, 475
 - desmethylinipramine, 475
 - isolation-induced fighting, 475
- Circling behavior
 - dopamine, 625
 - 6-hydroxydopamine, 625
 - morphine, 625
 - raphe nucleus, 625
 - serotonin, 625
- Classical-operant transfer
 - discrimination learning, 101
 - dopamine, 101
 - pimozide, 101
 - two-process learning theory, 101
- Clozapine
 - amphetamine, 49
 - amygdala, 49
 - haloperidol, 49
 - unit activity, 49
- Coca
 - activity, 725
 - cocaine, 725
 - eating, 725
- Cocaine
 - activity, 725
 - N-allylnorcocaine, 81
 - amygdala, 397
 - brain weight, 409
 - coca, 725
 - discriminative stimulus, 81
 - eating, 725
 - electric shock, 423
 - kindling, 397
 - lidocaine, 397
 - norcocaine, 81
 - olfactory bulb, 397
 - operant behavior, 423
 - prepyriform cortex, 397
 - seizures, 397, 409
- Codeine
 - drug self-administration, 805
 - naloxone, 805
- operant behavior, 805
- thebaine, 805
- Colchicine
 - axonal transport, 863
 - memory, 863
 - species differences, 863
 - tubulin, 863
 - uptake, 863
- Cold-water swims
 - analgesia, 645
 - p-chlorophenylalanine, 645
 - 2-deoxy-D-glucose, 645
 - inescapable foot shock, 645
 - morphine, 645
 - pain, 645
- Combined specific therapy
 - caudate nucleus, 273
 - determinant structure, 273
 - diazepam, 273
 - GABA, 273
 - haloperidol, 273
 - lithium, 273
 - stereotypy, 273
- Conditioned avoidance
 - chlorpromazine, 433
 - dopamine, 433
 - movement initiation, 433
- Conflict behavior
 - DOM, 617
 - LSD, 617
 - methaqualone, 617
 - pentobarbital, 617
 - serotonin, 617
- Conflict situation
 - benzodiazepines, 219
 - hypothalamus, 219
 - self-stimulation, 219
- Consummatory behavior
 - approach-avoidance conflict, 447
 - caloric intake, 447
 - iron deficiency, 447
 - pituitary-adrenal system, 447
 - taste aversion, 447
- Copulation
 - endorphin, 251
 - naloxone, 251
 - refractory period, 251
 - sexual reflexes, 251
- Corticosterone
 - naloxone, 749
 - stress, 749
- Critical periods
 - ethanol, 57
 - fetal alcohol syndrome, 57
 - prenatal, 57
 - sensorimotor development, 57
 - viability, 57
- Cross tolerance
 - analgesia, 75
 - catatonia, 75
 - inescapable shock, 677
 - learned helplessness, 677
 - morphine, 677
 - opiates, 75
 - receptors, 75
 - stress-induced analgesia, 677
 - tolerance, 75
- CS modality
 - amphetamine, 121
 - avoidance behavior, 121
 - genetics, 121
 - scopolamine, 121
- Cyanamide
 - acetaldehyde, 377
 - aldehyde dehydrogenase, 377

- calcium carbimide, 377
- ethanol, 377
- 4-methylpyrazole, 377
- Cyclic nucleotide phosphodiesterase
- cAMP, 603
- Drosophila melanogaster*, 603
- learning, 603
- locomotor activity, 603
- temperature-sensitive mutants, 603
- x-chromosome, 603

- Decarboxylase inhibitors
 - blood pressure, 895
 - drinking, 889
 - heart rate, 895
 - 5-hydroxytryptophan, 889
 - renin, 895
 - serotonin, 889, 895
 - temperature, 895
- Defensiveness
 - acetylcholine, 35
 - aggression, 35
 - dopamine, 35
 - glutamate, 35
 - hyperreactivity, 35
 - norepinephrine, 35
 - septum, 35
- Deficiency
 - pyrithiamine, 153
 - string test, 153
 - thiamine, 153
- Dendrites
 - behavioral inhibition, 455
 - DNA, 455
 - learning, 455
 - protein, 455
- 2-Deoxyglucose
 - angiotensin, 549
 - drinking, 549
 - eating, 549
 - insulin, 549
 - opiates, 549
 - opiate antagonists, 549
 - polyethylene glycol, 549
 - tail-pinch, 549
- 2-Deoxy-D-glucose
 - analgesia, 579, 645
 - p-chlorophenylalanine, 645
 - cold-water swims, 645
 - inescapable foot shock, 645
 - intraventricular administration, 579
 - morphine, 645
 - pain, 579, 645
- Desmethylimipramine
 - aggression, 475
 - chronic treatment, 475
 - isolation-induced fighting, 475
- Determinant structure
 - caudate nucleus, 273
 - combined specific therapy, 273
 - diazepam, 273
 - GABA, 273
 - haloperidol, 273
 - lithium, 273
 - stereotypy, 273
- Development
 - activity, 5
 - amphetamine, 5
 - behavioral activation, 831
 - dopamine, 5
 - 6-hydroxydopamine, 5
 - mouthing behavior, 831
 - neonatal exposure, 831
 - quipazine, 831
 - serotonin, 831
 - sex differences, 5
- Diazepam
 - benzodiazepines, 839
 - bioactivity, 839
 - caudate nucleus, 273
 - combined specific therapy, 273
 - determinant structure, 273
 - endogenous ligand, 839
 - GABA, 273
 - haloperidol, 273
 - histamine, 333
 - lithium, 273
 - peptide, 839
 - stereotypy, 273
 - stress, 333
- Dietary quinine
 - drug metabolism, 283
 - lesions, 283
 - ventromedial hypothalamus, 283
- Dietary self-selection
 - amphetamine, 539
 - anorexia, 539
 - caloric intake, 539
 - carbohydrate, 539
 - fat, 539
 - protein, 539
- Diethylthiocarbamate
 - amnesia, 713
 - catecholamines, 713
 - guanethidine, 713
 - memory, 713
 - passive avoidance, 713
- 5,7-Dihydroxytryptamine
 - hallucinogens, 915
 - medial forebrain bundle, 915
 - operant behavior, 915
 - serotonin, 915
- 2,5-Dimethoxy-4-methylamphetamine
 - abnormal behavior, 89
 - p-chlorophenylalanine, 89
 - head twitch, 89
 - lesions, 89
 - locomotion, 89
 - LSD, 89
 - mescaline, 89
 - methysergide, 89
 - raphe nucleus, 89
 - serotonin, 89
- Discriminated avoidance
 - antipsychotic drugs, 181
 - Sidman avoidance, 181
- Discrimination learning
 - aceperone, 849
 - classical-operant transfer, 101
 - dopamine, 101
 - marmoset, 849
 - norepinephrine, 849
 - pimozide, 101
 - two-process learning theory, 101
- Discriminative stimulus
 - 4-alkyl-2,5-dimethoxyamphetamine, 287
 - 4-alkyl-2,5-dimethoxyphenylisopropylamines, 287
 - n-allylnorcocaine, 81
 - cocaine, 81
 - DOET, 287
 - DOM, 287
 - drug discrimination, 97
 - ethanol, 97
 - 5-methoxy-N,N-dimethyltryptamine, 287
 - monkey, 241
 - morphine, 241
 - naloxone, 97
 - naltrexone, 97
 - narcotic antagonists, 241

- norcocaine, 81
- opiates, 97
- receptors, 287
- serotonin, 287
- DNA
 - behavioral inhibition, 455
 - dendrites, 455
 - learning, 455
 - protein, 455
- Dobutamine
 - blood pressure, 313
 - cardiac output, 313
 - heart rate, 313
 - left ventricular dP/dt, 313
 - practolol, 313
 - stress, 313
- DOET
 - 4-alkyl-2,5-dimethoxyamphetamine, 287
 - 4-alkyl-2,5-dimethoxyphenylisopropylamines, 287
 - discriminative stimulus, 287
 - DOM, 287
 - 5-methoxy-N,N-dimethyltryptamine, 287
 - receptors, 287
 - serotonin, 287
- DOM
 - 4-alkyl-2,5-dimethoxyamphetamine, 287
 - 4-alkyl-2,5-dimethoxyphenylisopropylamines, 287
 - conflict behavior, 617
 - discriminative stimulus, 287
 - DOET, 287
 - hallucinogens, 595
 - LSD, 595, 617
 - mescaline, 595
 - methaqualone, 617
 - 5-methoxy-N,N-dimethyltryptamine, 287
 - operant behavior, 595
 - pentobarbital, 617
 - phenobarbital, 595
 - receptors, 287
 - serotonin, 287, 595, 617
- Dopamine
 - acetylcholine, 35
 - acrylamide, 533
 - activity, 5
 - aggression, 35
 - amphetamine, 5
 - anorexia, 481
 - apomorphine, 753
 - benzodiazepine, 693
 - β -carbolines, 693
 - catalepsy, 469
 - caudate nucleus, 481
 - chicken, 469
 - chlorpromazine, 433
 - circling behavior, 625
 - classical-operant transfer, 101
 - conditioned avoidance, 433
 - defensiveness, 35
 - development, 5
 - discrimination learning, 101
 - drinking, 385
 - endogenous ligand, 693
 - extinction, 201
 - glutamate, 35
 - harmaline, 693
 - 6-hydroxydopamine, 5, 85, 625
 - 5-hydroxytryptophan, 385
 - hyperreactivity, 35
 - L.A.A.M., 753
 - lithium chloride, 85
 - mediation of submissive behavior, s95
 - methamphetamine, 481
 - methylamphetamine, 85
 - morphine, 625
 - movement initiation, 433
 - muscarinic, 693
 - neurotransmitters, 533
 - norepinephrine, 35
 - opiates, 753
 - pimozide, 101, 201
 - raphe nucleus, 625
 - receptors, 201, 533, 693, 753
 - renin-angiotensin system, 385
 - septum, 35
 - serotonin, 469, 625, 693
 - sex differences, 5
 - specificity, 693
 - stereotypy, 753
 - taste aversion, 85
 - tolerance, 481
 - tonic immobility, 469
 - tryptophan, 469
 - two-process learning theory, 101
 - water reinforcement, 201
- Drinking
 - acetaldehyde, 107
 - activity, 569
 - aldehyde dehydrogenase, 107
 - angiotensin, 549
 - t-butanol, 633
 - caffeine, 235
 - cat, 419
 - decarboxylase inhibitors, 889
 - 2-deoxyglucose, 549
 - dopamine, 385
 - eating, 235, 419, 549, 569
 - ethanol, 107, 633
 - food deprivation, 419
 - genetics, 107
 - 5-hydroxytryptophan, 385, 889
 - insulin, 549
 - naloxone, 419, 569
 - opiates, 549
 - opiate antagonists, 549
 - physical dependence, 633
 - polyethylene glycol, 549
 - preference, 107
 - renin-angiotensin system, 385
 - schedule-induced behavior, 633
 - serotonin, 889
 - tail-pinch, 549
 - water deprivation, 419
- Drinking device
 - ethanol, 871
 - etonitazene, 871
 - operant behavior, 871
- Drosophila melanogaster*
 - cAMP, 603
 - cyclic nucleotide phosphodiesterase, 603
 - learning, 603
 - locomotor activity, 603
 - temperature-sensitive mutants, 603
 - x-chromosome, 603
- Drug
 - aceperone, 849
 - N-acetyl-L-glutamate, 919
 - acrylamide, 527, 533
 - alcohol, s47, s79
 - 4-alkyl-2,5-dimethoxyamphetamines, 287
 - 4-alkyl-2,5-dimethoxyphenylisopropylamines, 287
 - d,l-allylglycine, s13
 - N-allylnorcocaine, 81
 - aminoxyacetic acid, s47
 - aminophylline, 827
 - amitriptyline, s33, 129
 - amphetamine, 5, 17, 49, s109, 117, 121, 159, 269, 345, 439, 507, 539, 661, 683, 799, 877
 - d-amphetamine, s95, s103
 - (+)-amphetamine, s47
 - apomorphine, 17, s47, s95, 339, 469, 493, 507, 741, 753

aspirin, s47
atropine, 35, 67
barbital, s47
benserazide, 889, 895
bicuculline, s53
bromazepam, 219
bromocriptine, 371
t-butanol, 633
butrophanol, 241, 689
caffeine, s47, 235, 683, 827
calcium carbimide, 377
captopril, 385
carbachol, 35, 67
carbamazepine, 507
carbidopa, 889, 895
 β -carbolines, 693
3-carboxy-1,2,3,4-tetrahydroisoquinoline, 639
carpipramine, 181
cathinone, 97
chlordiazepoxide, s43, s47, s103
p-chloroamphetamine, 463
p-chlorophenylalanine, 11, 89, 293, 645, 669, 911
m-chlorophenylpiperazine, 799
chlorpromazine, s47, 353, 433
cinanserin, 463
clocapramine, 181
clomipramine, s33
clonidine, 385
clotiapine, 181
clozapine, 49, 181
coca, 725
cocaine, 81, s109, 339, 397, 409, 423, 725
codeine, s47, 805
codorphone, 689
colchicine, 863
cyanamide, 377
cyclazocine, 241
2-deoxyglucose, 549, 579, 645
desipramine, s47
desmethylimipramine, 475
diazepam, s47, 219, 273, 333, 507, 839
diethylthiocarbamate, 713
diethylpropion, 799
dihydroergotoxine, s47
6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, 637
5,6-dihydroxytryptamine, s47
5,7-dihydroxytryptamine, 915
2,5-dimethoxy-4-methylamphetamine, 89, 287, 595, 617, 915
diphenylhydantoin, 507
n-dipropylacetate, s13
dobutamine, 313
DOET, 287
DU 27725, s61
ethanol, 23, 41, 57, 97, 107, 143, 165, 207, 227, 263, 293, 353, 377, 633, 733, 835, 857, 871
ethosuximide, 507
N-ethyl-l-phenylcyclohexylamine, 213
etonitazene, 871
fenfluramine, 463, 469, 661, 799
flurazepam, 811
glutamic acid diethyl ester, 223
guaiphenesine, s47
guanethidine, 713
haloperidol, s47, 49, 67, s95, 169, 273, 345, 385, 469, 507, 543
harmane, 693
hydroxybutyrate, s47
6-hydroxy DOPA, s47
6-hydroxydopamine, 5, s7, s29, s47, 85, 625
5-hydroxytryptophan, 385, 889, 895
hypoxanthine, 589
imipramine, s7, s33, s47, 129
inosine, 589
iprindole, 129
irazepine, 487
kenazepine, 487
ketamine, 23, 213
ketocyclazocine, 241
khat, 907
kynurenine, 589
LAAM 393, 753
lead, 877
levallorphan, 241
lidocaine, 35, 67, 397
lisuride, 339
lithium, s7
lithium chloride, 41, 85, 273, 439
lorazepam, s43
LSD, s47, 89, 339, 595, 617, 915
maprotiline, s33
5-MeODMT, s95
mescaline, 89, 595, 915
methadone, 561, 653
methamphetamine, 481
methaqualone, s47, 617
methiothepin, 707
5-methoxy-N,N-dimethyltryptamine, 287
methylamphetamine, 85, 117
methylphenidate, 117, 683
4-methylpyrazole, 377
methysergide, 89, 889
metrazol, 23
mianserin, 129
morphine, s103, 133, 139, 169, 241, 325, 361, 393, 575, 625, 645, 677, 689, 757, 779
muscimol hydrobromide, s13
nalbuphine, 241, 689
nalmexone, 241
nalorphine, 241, 549
naloxone, 97, 113, 247, 251, 299, 325, 361, 419, 545, 569, 575, 631, 749, 779, 805, 881
naltrexone, 97, 561, 881
nictinamide, 589
nicotine, 175, 683
norcocaine, 81
norharmane, 693
nortriptyline, 823
ORG-2766, 845
paracetamol, s47
pargyline, s7
pentazocine, 241, 689
pentobarbital, 23, s47, 269, 507, 617
pentylentetrazol, 487, 589
phenacetin, s47
phencyclidine, 213
phenibut, s53
phenobarbital, s47, 405, 507, 595, 811
phenoxybenzamine, 371, 517, 707
phentolamine, 67
1-(1-phenylcyclohexyl) morpholine, 213
phenylpyrrolidon, s53
physostigmine, 35, 321
picrotoxin, s13, 23, s47, s53, 613
pimozide, s95, 101, 181, 201, 543
piracetam, s47
practolol, 313
profadol, 241
propericiazine, 181
propranolol, 67, 385
d,l-propranolol, s7
quipazine, 339, 463, 831
reserpine, 707
rubidium, s7
scopolamine, 1, s47, 121, 321, 669
secobarbital, 353
sodium, s7
spiclomazine, 181
spiperone, 385
strychnine, 193
sulpiride, 181
 Δ^9 -tetrahydrocannabinol, 745

tetrahydronorharmine, 693
 thalidomide, 811
 thebaine, 805
 theophylline, 683, 701, 827
 1-[1-(2-thienyl)cyclohexyl] piperidine, 213
 thioridazine, 181
 thiothixene, 181
 tolazocine, 67
 TR5257, 689
 TR5400, 689
 trifluoperazine, s47, s95
 triflupromazine, 181
 trimethadione, 507
 1-tryptophan, s47
 valproate, s47
 WIN-44,441, 549
 WY-16,225, 241

Drug discrimination
 amphetamine, 269
 caffeine, 683
 discriminative stimulus, 97
 ethanol, 97
 extended schedule of responding, 269
 monkey, 213
 naloxone, 97
 naltrexone, 97
 operant behavior, 683
 opiates, 97
 pentobarbital, 269
 phencyclidine, 213
 phencyclidine analogues, 213
 schedule-controlled behavior, 213

Drug-induced stimulus control
 ethanol, 23
 extended schedule transfer, 23
 pentobarbital, 23

Drug metabolism
 dietary quinine, 283
 lesions, 283
 ventromedial hypothalamus, 283

Drug preference
 abuse liability, 159
 adjunctive behavior, 405
 amphetamine, 159
 human, 159
 phenobarbital, 405
 physical dependence, 405
 POMS, 159
 schedule-induced behavior, 405
 subjective effects, 159
 withdrawal, 405

Drug reinforcement
 ethanol, 263
 spatial aversion, 263

Drug self-administration
 codeine, 805
 naloxone, 805
 operant behavior, 805
 pneumatic syringe, 573
 thebaine, 805

DU 27725
 anti-aggressive properties, s61

Eating
 activity, 443, 569, 725
 amphetamine, 661
 angiotensin, 549
 anorectics, 799
 anorexia, 799
 behavioral teratology, 653
 body weight, 653
 bombesin, 149
 caffeine, 235
 cat, 419
 coca, 725
 cocaine, 725
 2-deoxyglucose, 549
 drinking, 235, 419, 549, 569
 fenfluramine, 661
 food deprivation, 419
 food restriction, 443
 glucose, 149
 hypothalamic, 443
 insulin, 549
 methadone, 653
 naloxone, 419, 569
 opiates, 549
 opiates antagonists, 549
 perinatal exposure, 653
 polyethylene glycol, 549
 runway behavior, 799
 satiety, 149
 skeletal growth, 443
 tail pinch, 149, 549
 thermoregulation, 653
 tolerance, 661
 water deprivation, 419

Electric shock
 cocaine, 423
 operant behavior, 423

Electrophysiology
 cerebellum, 227
 ethanol, 227
 genetics, 227
 ethanol, 227
 sleep time, 227

Endogenous ligand
 benzodiazepine, 693, 839
 bioactivity, 839
 β -carbolines, 693
 diazepam, 839
 dopamine, 693
 harmine, 693
 muscarinic, 693
 peptide, 839
 receptors, 693
 serotonin, 693
 specificity, 693

Endorphin
 copulation, 251
 naloxone, 113, 251, 299
 refractory period, 251
 sexual reflexes, 251
 social crowding, 299
 stress, 113
 taste aversion, 299

Environmental stimuli
 analgesia, 757
 hot plate, 757
 morphine, 757
 tolerance, 757

Enzymes
 fat cell, 701
 lipolysis, 701
 phospholipid, 701
 theophylline, 701

Ethanol
 acetaldehyde, 107, 377
 aldehyde dehydrogenase, 107, 377
 binge vs continuous drug regimen, 207
 body weight level, 857
 bone sodium, 41
 t-butanol, 633
 calcium carbimide, 377
 castration, 293
 cerebellum, 227
 chlorpromazine, 353
 critical periods, 57

- cyanamide, 377
- discriminative stimulus, 97
- drinking, 107, 633
- drinking device, 871
- drug discrimination, 97
- drug-induced stimulus control, 23
- drug reinforcement, 263
- electrophysiology, 227
- etonitazene, 871
- extended schedule transfer, 23
- extracellular water, 41
- fetal alcohol syndrome, 57
- genetics, 107, 165, 227
- hippocampus, 227
- human, 353
- intoxication, 207, 835
- intracellular sodium, 41
- LH, 293
- lithium, 41
- melatonin, 143
- metabolic tolerance, 165
- 4-methylpyrazole, 377
- motor impairment, 835
- naloxone, 97
- naltrexone, 97
- neurotransmitters, 733
- operant behavior, 871
- opiates, 97
- PCPA, 293
- pentobarbital, 23
- physical dependence, 633, 733
- pineal glands, 143
- preference, 107
- prenatal, 57
- regional differences, 733
- schedule induced behavior, 633
- schedule induced polydipsia, 857
- secobarbital, 353
- sensorimotor development, 57
- serotonin, 293
- sex differences, 857
- silicone delivery system, 207
- sleep time, 227
- social interaction, 353
- spatial aversion, 263
- speech, 353
- strain differences, 857
- subjective reports, 353
- tissue tolerance, 165
- tolerance, 165
- viability, 57
- withdrawal, 207
- Etonitazene
 - drinking device, 871
 - ethanol, 871
 - operant behavior, 871
- Evoked potentials
 - caudate nucleus, 193
 - lateral geniculate, 193
 - occipital cortex, 193
 - passive avoidance, 193
 - strychnine, 193
- Excessive grooming
 - caudate nucleus, 305
 - hippocampal damage, 305
 - membrane phosphorylation, 305
 - neocortex, 305
 - nucleus accumbens, 305
- Extended schedule of responding
 - amphetamine, 269
 - drug discrimination, 269
 - pentobarbital, 269
- Extended schedule transfer
 - drug-induced stimulus control, 23
 - ethanol, 23
 - pentobarbital, 23
- Extinction
 - dopamine, 201
 - autoshaping, 543
 - haloperidol, 543
 - Pavlovian conditioning, 543
 - pimozide, 201, 543
 - receptors, 201
 - stimulation, 543
 - water reinforcement, 201
- Extracellular water
 - bone sodium, 41
 - ethanol, 41
 - intracellular sodium, 41
 - lithium, 41
- Fat
 - amphetamine, 539
 - anorexia, 539
 - caloric intake, 539
 - carbohydrate, 539
 - dietary self-selection, 539
 - protein, 539
- Fat cell
 - enzymes, 701
 - lipolysis, 701
 - phospholipid, 701
 - theophylline, 701
- Fenfluramine
 - amphetamine, 661
 - body weight regulation, 661
 - eating, 661
 - tolerance, 661
- Ferret
 - blood sampling, 225
 - intravenous drug administration, 255
 - jugular catheter, 255
- Fetal alcohol syndrome
 - critical periods, 57
 - ethanol, 57
 - prenatal, 57
 - sensorimotor development, 57
 - viability, 57
- Fighting
 - 6-hydroxydopamine in cats, s29
- Food deprivation
 - apomorphine, 493
 - cat, 419
 - drinking, 419
 - eating, 419
 - naloxone, 419
 - pharmacokinetics, 493
 - stereotypy, 493
 - water deprivation, 419
- Food restriction
 - activity, 443
 - eating, 443
 - hypothyroidism, 443
 - skeletal growth, 443
- GABA
 - caudate, 273
 - combined specific therapy, 273
 - determinant structure, 273
 - diazepam, 273
 - haloperidol, 273
 - hippocampus, 613
 - lithium, 273
 - memory consolidation, 613
 - picROTOXIN, 613
 - stereotypy, 273
- GABAergic system
 - involvement in shock-induced aggression, s13

Genetics
 acetaldehyde, 107
 aldehyde dehydrogenase, 107
 amphetamine, 124
 apomorphine, 741
 avoidance behavior, 124
 cerebellum, 227
 CS modality, 124
 drinking, 107, 165
 electrophysiology, 227
 ethanol, 107, 227
 hippocampus, 227
 locomotor activity, 741
 metabolic tolerance, 165
 preference, 107
 scopolamine, 124
 sleep time, 227
 tissue tolerance, 165
 tolerance, 165

pGlu⁶ (SP_{6,11})
 analgesia, 11
 p-chlorophenylalanine, 11
 lesions, 11
 raphe nucleus, 11
 serotonin, 11
 species differences, 11
 substance P, 11

Glucose
 bombesin, 149
 eating, 149
 glycerol, 517
 insulin, 517
 neurotensin, 149
 obesity, 517
 phenoxybenzamine, 517
 plasma catecholamines, 517
 satiety, 149
 stress, 517
 sympatho-adrenal system, 517
 tail pinch, 149
 thermogenesis, 517
 Zucker rat, 517

Glutamate
 N-acetyl-L-glutamate, 919
 acetylcholine, 35
 aggression, 35
 amnesia, 919
 aspartate, 67
 atropine, 67
 carbachol, 67
 chicken, 919
 defensiveness, 35
 dopamine, 35
 haloperidol, 67
 hyperreactivity, 35
 intracranial injection, 67
 lidocaine, 67
 norepinephrine, 35
 oculomotor nucleus, 67
 phentolamine, 67
 proline, 919
 propranolol, 67
 septum, 35
 tolazocine, 67

Glutamic acid diethyl ester
 central excitatory processes, 223
 instrumental learning, 223

Glycerol
 glucose, 517
 insulin, 517
 obesity, 517
 phenoxybenzamine, 517
 plasma catecholamines, 517
 stress, 517
 sympatho-adrenal system, 517
 thermogenesis, 517
 Zucker rat, 517

Goat
 activity, 901
 cardiovascular effects, 901
 intraventricular administration, 901
 TRH, 901

Gonadectomy
 amphetamine, 17
 apomorphine, 17
 locomotor activity, 17
 sex differences, 17
 stereotyped behavior, 17

Growth hormone
 isolation-induced aggression in mice, s85

Guanethidine
 amnesia, 713
 catecholamines, 713
 diethyldithiocarbamate, 713
 memory, 713
 passive avoidance, 713

Hallucinogens
 abortive-groom, 339
 animal models, 339
 cat, 339
 5,7-dihydroxytryptamine, 915
 DOM, 595
 limb-flick, 339
 LSD, 595
 medial forebrain bundle, 915
 mescaline, 595
 operant behavior, 595, 915
 phenobarbital, 595
 serotonin, 595, 915

Haloperidol
 amphetamine, 49, 345
 amygdala, 49, 169
 aspartate, 67
 atropine, 67
 autoshaping, 543
 carbachol, 67
 catalepsy, 169, 273
 caudate nucleus, 169
 clozapine, 49
 combined specific therapy, 273
 determinant structure, 273
 diazepam, 273
 extinction, 543
 GABA, 273
 glutamate, 67
 intracranial injection, 67
 lidocaine, 67
 lithium, 273
 morphine, 169
 oculomotor nucleus, 67
 Pavlovian conditioning, 543
 phentolamine, 67
 pimozide, 543
 primate, 345
 propranolol, 67
 reticular formation, 169
 reversal learning, 345
 stereotypy, 273
 stimulation, 543
 tolazocine, 67
 unit activity, 49

Harmaline
 benzodiazepine, 693
 β -carbolines, 693
 dopamine, 693
 endogenous ligand, 693

- muscarinic, 693
 - receptors, 693
 - serotonin, 693
 - specificity, 693
- Head twitch
 - abnormal behavior, 89
 - p-chlorophenylalanine, 89
 - 2,5-dimethoxy-4-methylamphetamine, 89
 - lesions, 89
 - locomotion, 89
 - LSD, 89
 - mescaline, 89
 - methysergide, 89
 - raphe nucleus, 89
 - serotonin, 89
- Heart rate
 - blood pressure, 313, 895
 - cardiac output, 313
 - decarboxylase inhibitors, 895
 - dobutamine, 313
 - left ventricular dP/dt, 313
 - practolol, 313
 - renin, 895
 - serotonin, 895
 - stress, 313
 - temperature, 895
- Heart rate conditioning
 - amygdala central nucleus, 497
 - opiates, 497
 - rabbit, 497
 - receptors, 497
- Hibernation
 - MAO, 773
 - serotonin, 773
- Hippocampal damage
 - caudate nucleus, 305
 - excessive grooming, 305
 - membrane phosphorylation, 305
 - neocortex, 305
 - nucleus accumbens, 305
- Hippocampus
 - behavioral reactivity, 815
 - cerebellum, 227
 - electrophysiology, 227
 - ethanol, 227
 - GABA, 613
 - genetics, 227
 - memory consolidation, 613
 - norepinephrine, 815
 - picrotoxin, 613
 - serotonin, 815
 - sleep time, 227
- Histamine
 - diazepam, 333
 - stress, 333
- Hormonal effects
 - sexual dimorphism and aggression, s89
- Hormone
 - ACTH, 845
 - angiotensin, 385, 549
 - corticosterone, 749, 910
 - estradiol, s89, 910
 - growth hormone, s89
 - insulin, 517, 549
 - LH, 293
 - melatonin, 143
 - MSH, 845
 - renin, 385, 895
 - testosterone, s89, 910
 - TRH, 683, 901
- Hot plate
 - analgesia, 757
 - environmental stimuli, 757
 - morphine, 757
 - tolerance, 757
- Human
 - abuse liability, 159
 - amphetamine, 159
 - chlorpromazine, 353
 - drug preference, 159
 - ethanol, 353
 - POMS, 159
 - secobarbital, 353
 - social interaction, 353
 - speech, 353
 - subjective effects, 159, 353
- 6-Hydroxydopamine
 - activity, 5
 - amphetamine, 5
 - circling behavior, 625
 - development, 5
 - dopamine, 5, 85, 625
 - lithium chloride, 85
 - methylamphetamine, 85
 - morphine, 625
 - raphe nucleus, 625
 - serotonin, 625
 - sex differences, 5
 - taste aversion, 85
 - ventricular injection and aggression in cats, s29
- 5-Hydroxyindoleacetic acid
 - ambulation, 259
 - non-esterified fatty acid, 259
 - portocaval anastomosis, 259
 - serotonin, 259
- 5-Hydroxytryptophan
 - decarboxylase inhibitors, 889
 - dopamine, 385
 - drinking, 385, 889
 - renin-angiotensin system, 385
 - serotonin, 889
- Hyperactivity
 - activity, 877
 - amphetamine, 877
 - animal models, 877
 - lead, 877
 - light-dark cycle, 877
- Hyperreactivity
 - acetylcholine, 35
 - aggression, 35
 - defensiveness, 35
 - dopamine, 35
 - glutamate, 35
 - norepinephrine, 35
 - septum, 35
- Hypnotics
 - light-dark cycle, 811
 - sleep, 811
- Hypothalamus
 - benzodiazepines, 219
 - p-chlorophenylalanine, 910
 - conflict situation, 219
 - self-stimulation, 219
 - serotonin, 910
 - steroidogenesis, 910
- Hypothermia
 - jumping, 575
 - morphine, 575
 - naloxone, 575
 - physical dependence, 575
- Hypothyroidism
 - activity, 443
 - food restriction, 443
 - skeletal growth, 443
- Hypoxanthine
 - inosine, 589
 - kynurenine, 589
 - nicotinamide, 689
 - pentyleneetetrazol, 589
 - seizures, 589

- Imipramine
 - aggression, 129
 - amitriptyline, 129
 - iprindole, 129
 - mianserin, 129
- Induced psychopathology
 - “speed drugs”, s109
- Inescapable shock
 - analgesia, 645
 - p-chlorophenylalanine, 645
 - cold-water swims, 645
 - cross tolerance, 677
 - 2-deoxy-D-glucose, 645
 - learned helplessness, 677
 - morphine, 645, 677
 - pain, 645
 - stress-induced analgesia, 677
- Inosine
 - hypoxanthine, 589
 - Rynurenine, 589
 - nicotinamide, 589
 - pentylenetetrazol, 589
 - seizures, 589
- Instrumental learning
 - central excitatory processes, 223
 - glutamic acid diethyl ester, 223
- Insulin
 - angiotensin, 549
 - 2-deoxyglucose, 549
 - drinking, 549
 - eating, 549
 - glucose, 517
 - glycerol, 517
 - obesity, 517
 - opiate antagonists, 549
 - opiates, 549
 - phenoxybenzamine, 517
 - plasma catecholamines, 517
 - polyethylene glycol, 549
 - stress, 517
 - sympatho-adrenal system, 517
 - tail-pinch, 549
 - thermogenesis, 517
 - Zucker rat, 517
- Intoxication
 - binge vs continuous drug regimen, 207
 - ethanol, 207, 835
 - motor impairment, 835
 - silicone delivery system, 207
 - withdrawal, 207
- Intracellular sodium
 - bone sodium, 41
 - ethanol, 41
 - extracellular water, 41
 - lithium, 41
- Intracerebroventricular injection
 - amphetamine, 439
 - lithium, 439
 - locomotor activity, 439
- Intracranial injection
 - aspartate, 67
 - atropine, 67
 - carbachol, 67
 - glutamate, 67
 - haloperidol, 67
 - lidocaine, 67
 - oculomotor nucleus, 67
 - phentolamine, 67
 - propranolol, 67
 - tolazocine, 67
- Intraperitoneal infusion
 - morphine substitution, 689
 - narcotic antagonist analgesic, 689
 - physical dependence, 689
- Intravenous drug administration
 - blood sampling, 255
 - ferret, 255
 - jugular catheter, 255
 - intravenous drug administration, 255
- Intraventricular injections
 - activity, 901
 - analgesia, 579
 - avoidance behavior, 639
 - cardiovascular effects, 901
 - 2-deoxy-D-glucose, 579
 - goat, 901
 - locomotor activity, 639
 - pain, 579
 - tetrahydroisoquinolines, 639
 - TRH, 901
- Iprindole
 - aggression, 129
 - amitriptyline, 129
 - imipramine, 129
 - mianserin, 129
- Irazepine
 - benzodiazepine, 487
 - benazepine, 487
 - pentylenetetrazol, 487
 - receptors, 487
- Iron deficiency
 - approach-avoidance conflict, 447
 - caloric intake, 447
 - consummatory behavior, 447
 - pituitary-adrenal system, 447
 - taste aversion, 447
- Isolation-induced fighting
 - aggression, 475
 - antidepressants and mouse, s33
 - catecholaminergic drugs, s53
 - chronic treatment, 475
 - cyclic AMP, s7
 - cyclic GMP, s7
 - desmethylimipramine, 475
 - effects of neuropsychotropic drugs, s47
 - GABAergic drugs, s53
 - growth hormone effects in mice, s85
 - serotonergic drugs, s53
- Jugular catheter
 - blood sampling, 255
 - ferret, 255
 - intravenous drug administration, 255
- Jumping
 - hypothermia, 575
 - morphine, 575
 - naloxone, 575
 - physical dependence, 575
- Kenazepine
 - benzodiazepine, 487
 - irazepine, 487
 - pentylenetetrazol, 487
 - receptors, 487
- Ketamine
 - metrazol, 27
 - picrotoxin, 27
 - seizures, 27
 - status pathophysiology, 27
- Khat
 - cathinone, 907
 - taste aversion, 907
- Kindling
 - amygdala, 397
 - cocaine, 397
 - lidocaine, 397
 - olfactory bulb, 397
 - prepyriform cortex, 397
 - seizures, 397
- Kynurenine
 - hypoxanthine, 589

- inosine, 589
 - nicotinamide, 589
 - pentylentetrazol, 589
 - seizures, 589
- LAAM**
- abstinence, 393
 - apomorphine, 753
 - dopamine, 753
 - morphine, 393
 - opiates, 753
 - receptors, 753
 - schedule-controlled behavior, 393
 - stereotypy, 753
- Lateral geniculate**
- caudate nucleus, 193
 - evoked potentials, 193
 - occipital cortex, 193
 - passive avoidance, 193
 - strychnine, 193
- Lead**
- activity, 877
 - amphetamine, 877
 - animal models, 877
 - hyperactivity, 877
 - light-dark cycle, 877
- Learned helplessness**
- cross tolerance, 677
 - inescapable shock, 677
 - morphine, 677
 - nortriptyline, 823
 - stress, 823
 - stress-induced analgesia, 677
- Learning**
- behavioral inhibition, 455
 - cAMP, 603
 - cyclic nucleotide phosphodiesterase, 603
 - dendrites, 455
 - DNA, 455
 - Drosophila melanogaster*, 603
 - locomotor activity, 603
 - protein, 455
 - temperature-sensitive mutants, 603
 - x-chromosome, 603
- Left ventricular dP/dt**
- blood pressure, 313
 - cardiac output, 313
 - dobutamine, 313
 - heart rate, 313
 - practolol, 313
 - stress, 313
- Lesch-Nyhan syndrome**
- methylxanthines, 827
 - purines, 827
 - self-injury, 827
- Lesions**
- abnormal behavior, 89
 - analgesia, 11
 - p-chlorophenylalanine, 11, 89
 - dietary quinine, 283
 - 2,5-dimethoxy-4-methylamphetamine, 89
 - drug metabolism, 283
 - pGLU⁶(SP₆₋₁₁), 11
 - head twitch, 89
 - locomotion, 89
 - LSD, 89
 - mescaline, 89
 - methysergide, 89
 - raphe nucleus, 11, 89
 - serotonin, 11, 89
 - species differences, 11
 - substance P, 11
 - ventromedial hypothalamus, 283
- Lidocaine**
- amygdala, 397
 - aspartate, 67
 - atropine, 67
 - carbachol, 67
 - cocaine, 397
 - glutamate, 67
 - haloperidol, 67
 - intracranial injection, 67
 - kindling, 397
 - oculomotor nucleus, 67
 - olfactory bulb, 397
 - phentolamine, 67
 - prepyriform cortex, 397
 - propranolol, 67
 - seizures, 397
 - tolazocine, 67
- LH**
- castration, 293
 - ethanol, 293
 - PCPA, 293
 - serotonin, 293
- Light-dark cycle**
- activity, 877
 - amphetamine, 877
 - animal models, 877
 - hyperactivity, 877
 - hypnotics, 811
 - lead, 877
 - sleep, 811
- Limb-flick**
- abortive-groom, 339
 - animal models, 339
 - cat, 339
 - hallucinogens, 339
- Lipolysis**
- enzymes, 701
 - fat cell, 701
 - phospholipid, 701
 - theophylline, 701
- Lithium**
- amphetamine, 439
 - bone sodium, 41
 - caudate nucleus, 273
 - combined specific therapy, 273
 - determinant structure, 273
 - diazepam, 273
 - ethanol, 41
 - extracellular water, 41
 - GABA, 273
 - haloperidol, 273
 - intracellular sodium, 41
 - intracerebroventricular injection, 439
 - locomotor activity, 439
 - stereotypy, 273
- Lithium chloride**
- dopamine, 85
 - 6-hydroxydopamine, 85
 - methylamphetamine, 85
 - taste aversion, 85
- Locomotion**
- abnormal behavior, 89
 - amphetamine, 17, 439
 - apomorphine, 17, 741
 - avoidance behavior, 639
 - cAMP, 603
 - p-chlorophenylalanine, 89
 - cyclic nucleotide phosphodiesterase, 603
 - 2,5-dimethoxy-4-methylamphetamine, 89
 - Drosophila melanogaster*, 603
 - genetics, 741
 - gonadectomy, 17
 - head twitch, 89
 - intracerebroventricular injection, 439
 - intra-ventricular injection, 639

- learning, 603
- lesions, 89
- lithium, 439
- LSD, 89
- mescaline, 89
- methysergide, 89
- morphine, 361
- naloxone, 361
- physical dependence, 361
- raphe nucleus, 89
- serotonin, 89
- sex differences, 17
- stereotyped behavior, 17
- temperature-sensitive mutants, 603
- tetrahydroisoquinoline, 639
- tolerance, 361
- withdrawal, 361
- x-chromosome, 603
- Lordosis
 - monoamines, 707
 - reserpine, 707
 - sexual behavior, 745
 - spinal cord, 707
 - Δ^9 -tetrahydrocannabinol, 745
 - ultrasounds, 745
- LSD
 - abnormal behavior, 89
 - p-chlorophenylalanine, 89
 - conflict behavior, 617
 - 2,5-dimethoxy-4-methylamphetamine, 89
 - DOM, 595, 617
 - hallucinogens, 595
 - head twitch, 89
 - lesions, 89
 - locomotion, 89
 - mescaline, 89, 595
 - methaqualone, 617
 - methysergide, 89
 - operant behavior, 595
 - pentobarbital, 617
 - phenobarbital, 595
 - raphe nucleus, 89
 - serotonin, 89, 595, 617
- MAO
 - hibernation, 773
 - serotonin, 773
- Marmoset
 - aceperone, 849
 - discrimination learning, 849
 - norepinephrine, 849
- Medial forebrain bundle
 - 5,7-dihydroxytryptamine, 915
 - hallucinogens, 915
 - operant behavior, 915
 - serotonin, 915
- Melatonin
 - ethanol, 143
 - pineal gland, 143
- Membrane phosphorylation
 - caudate nucleus, 305
 - excessive grooming, 305
 - hippocampal damage, 305
 - neocortex, 305
 - nucleus accumbens, 305
- Memory
 - amnesia, 321, 713
 - axonal transport, 863
 - catecholamines, 713
 - cholinergic mechanisms, 321
 - colchicine, 863
 - diethyldithiocarbamate, 713
 - guanethidine, 713
 - passive avoidance, 713
 - physostigmine, 321
 - scopolamine, 321
 - species differences, 863
 - tubulin, 863
 - uptake, 863
- Memory consolidation
 - GABA, 613
 - hippocampus, 613
 - picrotoxin, 613
- Mental stereotypy
 - "speed drugs", s109
- Mescaline
 - abnormal behavior, 89
 - p-chloroamphetamine, 89
 - 2,5-dimethoxy-4-methylamphetamine, 89
 - DOM, 595
 - hallucinogens, 595
 - head twitch, 89
 - lesions, 89
 - locomotion, 89
 - LSD, 89, 595
 - methysergide, 89
 - operant behavior, 595
 - phenobarbital, 595
 - raphe nucleus, 89
 - serotonin, 89, 595
- Metabolic tolerance
 - ethanol, 165
 - genetics, 165
 - tissue tolerance, 165
 - tolerance, 165
- Methadone
 - behavioral teratology, 653
 - body weight, 653
 - eating, 653
 - naltrexone, 561
 - opiates, 561
 - perinatal exposure, 653
 - reproduction, 561
 - sexual behavior, 561
 - thermoregulation, 653
- Methamphetamine
 - anorexia, 481
 - caudate nucleus, 481
 - dopamine, 481
 - tolerance, 481
- Methaqualone
 - conflict behavior, 617
 - DOM, 617
 - LSD, 617
 - pentobarbital, 617
 - serotonin, 617
- Method
 - rapid method to evaluate acute ethanol intoxication in mice, 835
 - simple, reliable method for predicting physical dependence
 - liability of narcotic antagonist analgesics in the rat, 689
 - technique for chronic jugular catheterization in the ferret, 255
- 5-Methoxy-N,N-dimethyltryptamine
 - 4-alkyl-2,5-dimethoxyamphetamines, 287
 - 4-alkyl-2,5-dimethoxyphenyl-isopropylamines, 287
 - discriminative stimulus, 287
 - DOET, 287
 - DOM, 287
 - receptors, 287
 - serotonin, 287
- Methylamphetamine
 - amphetamine, 117
 - catecholamine depletion, 117
 - dopamine, 85
 - 6-hydroxydopamine, 85
 - lithium chloride, 85
 - methylphenidate, 117
 - neonatal, 117
 - taste aversion, 85

Methylphenidate
 amphetamine, 117
 catecholamine depletion, 117
 methylamphetamine, 117
 neonatal, 117

4-Methylpyrazole
 acetaldehyde, 377
 aldehyde dehydrogenase, 377
 calcium carbimide, 377
 cyanamide, 377
 ethanol, 377

Methylxanthines
 Lesch-Nyhan syndrome, 827
 purines, 827
 self-injury, 827

Methysergide
 abnormal behavior, 89
 p-chlorophenylalanine, 89
 2,5-dimethoxy-4-methylamphetamine, 89
 head twitch, 89
 lesions, 89
 locomotion, 89
 LSD, 89
 mescaline, 89
 raphe nucleus, 89
 serotonin, 89

Metrazol
 ketamine, 27
 picrotoxin, 27
 seizures, 27
 status pathophysiology, 27

MHPG
 norepinephrine, 729
 regional differences, 729
 stress, 729

Mianserin
 aggression, 129
 amitriptyline, 129
 imipramine, 129
 iprindole, 129

Microcomputer
 BASIC, 415
 operant research, 415

Model psychosis
 "speed drugs", s109

Monkey
 discriminative stimulus, 241
 drug discrimination, 213
 morphine, 241
 narcotic antagonists, 241
 phencyclidine, 213
 phencyclidine analogues, 213
 schedule-controlled behavior, 213

Monoamines
 lordosis, 707
 reserpine, 707
 spinal cord, 707

Morphine
 abstinence, 393
 amygdala, 169
 analgesia, 133, 139, 645, 757
 catalepsy, 169
 caudate nucleus, 169
 p-chlorophenylalanine, 645
 circling behavior, 625
 cold-water swims, 645
 cross tolerance, 677
 2-deoxy-D-glucose, 645
 discriminative stimulus, 241
 dopamine, 625
 environmental stimuli, 757
 haloperidol, 169
 hot plate, 757
 6-hydroxydopamine, 625
 hypothermia, 575
 inescapable shock, 645, 677
 jumping, 575
 LAAM, 393
 learned helplessness, 677
 locomotor activity, 361
 monkey, 241
 naloxone, 325, 361, 575, 779
 narcotic antagonists, 241
 pain, 645
 physical dependence, 361, 575, 779
 raphe nucleus, 625
 reticular formation, 169
 schedule-controlled behavior, 393
 self-stimulation, 325
 serotonin, 625
 stress-induced analgesia, 677
 substantia nigra, 325
 tail flick, 133, 139
 taste aversion, 779
 tolerance, 133, 139, 361, 757
 UCS pre-exposure, 779
 ventral tegmentum, 325
 withdrawal, 361

Morphine substitution
 intraperitoneal infusion, 689
 narcotic antagonist analgesia, 689
 physical dependence, 689

Motor impairment
 ethanol, 835
 intoxication, 835

Mouse-killing
 cyclic AMP, s7
 cyclic GMP, s7
 dietary tryptophan deprivation, s19
 raphe nuclei stimulation, s25

Mouthing behavior
 behavioral activation, 831
 development, 831
 neonatal exposure, 831
 quipazine, 831
 serotonin, 831

Movement initiation
 chlorpromazine, 433
 conditioned avoidance, 433
 dopamine, 433

Multidimensional analysis
 aging, 787
 odor, 787
 pyrazines, 787

Muscarinic
 benzodiazepine, 693
 B-carboline, 693
 dopamine, 693
 endogenous ligand, 693
 harmaline, 693
 receptors, 693
 serotonin, 693
 specificity, 693

Naloxone
 activity, 569
 antinociception, 631
 cat, 419
 codeine, 805
 copulation, 251
 corticosterone, 749
 discriminative stimulus, 97
 drinking, 419, 569
 drug discrimination, 97
 drug self-administration, 805
 eating, 419, 569
 endorphins, 113, 251, 299
 ethanol, 97
 food deprivation, 419

- hypothermia, 575
- jumping, 575
- locomotor activity, 361
- morphine, 325, 361, 575, 779
- naltrexone, 97, 881
- operant behavior, 805
- opiates, 97, 881
- physical dependence, 361, 575, 779
- refractory period, 251
- reinforcement thresholds, 247
- self-stimulation, 247, 325
- sexual behavior, 881
- sexual reflexes, 251, 8
- social crowding, 299
- stress, 113, 749
- substantia nigra, 325
- taste aversion, 299, 799
- thebaine, 805
- tolerance, 361
- UCS pre-exposure, 779
- vaginal stimulation, 631
- ventral tegmentum, 325
- water deprivation, 419
- withdrawal, 361
- Naltrexone
 - discriminative stimulus, 97
 - drug discrimination, 97
 - ethanol, 97
 - methadone, 561
 - naloxone, 97, 881
 - opiates, 97, 561, 881
 - reproduction, 561
 - sexual behavior, 561, 881
- Narcotic antagonists
 - discriminative stimulus, 241
 - monkey, 241
 - morphine, 241
- Narcotic antagonist analgesic
 - intraperitoneal infusion, 689
 - morphine substitution, 689
 - physical dependence, 689
- Neocortex
 - caudate nucleus, 305
 - excessive grooming, 305
 - hippocampal damage, 305
 - membrane phosphorylation, 305
 - nucleus accumbens, 305
- Neonatal
 - amphetamine, 117
 - behavioal activation, 831
 - catecholamine depletion, 117
 - development, 831
 - methylamphetamine, 117
 - methylphenidate, 117
 - mouthng behavior, 831
 - quipazine, 831
 - serotonin, 831
- Neuropsychotropic drugs
 - effects on attack, defense and escape, s47
- Neurotensin
 - bombesin, 149
 - eating, 149
 - glucose, 149
 - satiety, 149
 - tail pinch, 149
- Neurotransmitters
 - acrylamide, 527, 533
 - dopamine, 533
 - ethanol, 733
 - physical dependence, 733
 - receptors, 527, 533
 - regional differences, 733
- Nicotinamide
 - hypoxanthine, 589
 - inosine, 589
 - kynurenine, 589
 - pentylenetetrazol, 589
 - seizures, 589
- Nicotine
 - aggression, 175
 - shock thresholds, 175
- Non-esterified fatty acid
 - ambulation, 259
 - 5-hydroxyindoleacetic acid, 259
 - portocaval anastomosis, 259
 - serotonin, 259
- Norcocaine
 - cocaine, 81
 - discriminative stimulus, 81
 - N-allylnorcocaine, 81
- Norepinephrine
 - aceperone, 849
 - acetylcholine, 35
 - adenylate cyclase, 719
 - aggression, 35
 - behavioral reactivity, 815
 - defensiveness, 35
 - discrimination learning, 849
 - dopamine, 35
 - glutamate, 35
 - hippocampus, 815
 - hyperreactivity, 35
 - marmoset, 849
 - MHPG, 729
 - phosphodiesterase, 719
 - receptors, 719
 - regional differences, 729
 - septum, 35
 - serotonin, 815
 - stress, 719, 729
 - subsensitivity, 719
- Nortriptyline
 - learned helplessness, 823
 - stress, 823
- Nucleus accumbens
 - caudate nucleus, 305
 - excessive grooming, 305
 - hippocampal damage, 305
 - membrane phosphorylation, 305
 - neocortex, 305
- Obesity
 - glucose, 517
 - glycerol, 517
 - insulin, 517
 - phenoxybenzamine, 517
 - plasma catecholamines, 517
 - stress, 517
 - sympatho-adrenal system, 517
 - thermogenesis, 517
 - Zucker rat, 517
- Occipital cortex
 - caudate nucleus, 193
 - evoked potentials, 193
 - lateral geniculate, 193
 - passive avoidance, 193
 - strychnine, 193
- Oculomotor nucleus
 - aspartate, 67
 - atropine, 67
 - carbachol, 67
 - glutamate, 67
 - haloperidol, 67
 - intracranial injection, 67
 - lidocaine, 67
 - phentolamine, 67
 - propranolol, 67
 - tolazocine, 67

- Odor
 - aging, 787
 - multidimensional scaling, 787
 - pyrazines, 787
- Olfactory bulb
 - amygdala, 397
 - cocaine, 397
 - kindling, 397
 - lidocaine, 397
 - prepyriform cortex, 397
 - seizures, 397
- Operant behavior
 - caffeine, 683
 - cocaine, 423
 - codeine, 805
 - 5,7-dihydroxytryptamine, 915
 - DOM, 595
 - drinking device, 871
 - drug discrimination, 683
 - drug self-administration, 805
 - electric shock, 423
 - ethanol, 871
 - etonitazene, 871
 - hallucinogens, 595, 915
 - LSD, 595
 - medial forebrain bundle, 915
 - mescaline, 595
 - naloxone, 805
 - phenobarbital, 595
 - serotonin, 595, 915
 - thebaine, 805
- Operant research
 - BASIC, 415
 - microcomputer, 415
- Opiate antagonists
 - angiotensin, 549
 - 2-deoxyglucose, 549
 - drinking, 549
 - eating, 549
 - insulin, 549
 - opiates, 549
 - polyethylene glycol, 549
 - tail-pinch, 549
- Opiates
 - amygdala central nucleus, 497
 - analgesia, 75
 - angiotensin, 549
 - apomorphine, 753
 - catatonia, 75
 - cross-tolerance, 75
 - 2-deoxyglucose, 549
 - discriminative stimulus, 97
 - dopamine, 753
 - drinking, 549
 - drug discrimination, 97
 - eating, 549
 - ethanol, 97
 - heart rate conditioning, 497
 - insulin, 549
 - LAAM, 753
 - methadone, 561
 - naloxone, 97, 881
 - naltrexone, 97, 561, 881
 - opiate antagonists, 549
 - polyethylene glycol, 549
 - rabbit, 497
 - receptors, 75, 497, 753
 - reproduction, 561
 - sexual behavior, 561, 881
 - stereotypy, 753
 - tail-pinch, 549
 - tolerance, 75
- ORG-2766
 - ACTH/MSH, 845
 - blood brain barrier, 845
 - permeability, 845
 - regional cerebral blood flow, 845
- Pain
 - analgesia, 579, 645
 - p-chlorophenylalanine, 645
 - cold-water swims, 645
 - 2-deoxy-D-glucose, 579, 645
 - inescapable foot shock, 645
 - intraventricular injection, 579
 - morphine, 645
- Passive avoidance
 - amnesia, 713
 - catecholamines, 713
 - caudate nucleus, 193
 - chicken, 669
 - p-chlorophenylalanine, 669
 - diethyldithiocarbamate, 713
 - evoked potentials, 193
 - guanethidine, 713
 - lateral geniculate, 193
 - memory, 713
 - occipital cortex, 193
 - scopolamine, 669
 - strychnine, 193
- Pavlovian conditioning
 - autoshaping, 543
 - extinction, 543
 - haloperidol, 543
 - pimozide, 543
 - stimulation, 543
- PCPA
 - castration, 293
 - ethanol, 293
 - LH, 293
 - serotonin, 293
- Pentobarbital
 - amphetamine, 269
 - conflict behavior, 617
 - DOM, 617
 - drug discrimination, 269
 - drug-induced stimulus control, 23
 - ethanol, 23
 - extended schedule of responding, 269
 - extended schedule transfer, 23
 - LSD, 617
 - methaqualone, 617
 - serotonin, 617
- Perinatal exposure
 - behavioral teratology, 653
 - body weight, 653
 - eating, 653
 - methadone, 653
 - thermoregulation, 653
- Phenobarbital
 - adjunctive behavior, 405
 - DOM, 595
 - drug preference, 405
 - hallucinogens, 595
 - LSD, 595
 - mescaline, 595
 - operant behavior, 595
 - physical dependence, 405
 - schedule-induced behavior, 405
 - serotonin, 595
 - withdrawal, 405
- Pentylenetetrazol
 - benzodiazepine, 487
 - hypoxanthine, 589
 - inosine, 589
 - irazepine, 487
 - kenazepine, 487
 - kynurenine, 589

- nicotinamide, 589
- receptors, 487
- seizures, 589
- Peptide**
 - benzodiazepines, 839
 - bioactivity, 839
 - diazepam, 839
 - endogenous ligand, 839
- Permeability**
 - ACTH/MSH, 845
 - blood-brain barrier, 845
 - ORG-2766, 845
 - regional cerebral blood flow, 845
- Pharmacokinetics**
 - apomorphine, 493
 - food deprivation, 493
 - stereotypy, 493
- Phencyclidine**
 - drug discrimination, 213
 - monkey, 213
 - phencyclidine analogues, 213
 - schedule-controlled behavior, 213
- Phencyclidine analogues**
 - drug discrimination, 213
 - monkey, 213
 - phencyclidine, 213
 - schedule-controlled behavior, 213
- Phenoxybenzamine**
 - bromocriptine, 371
 - glucose, 517
 - glycerol, 517
 - insulin, 517
 - obesity, 517
 - plasma catecholamines, 517
 - REM sleep, 371
 - stress, 517
 - sympatho-adrenal system, 517
 - thermogenesis, 517
 - Zucker rat, 517
- Phentolamine**
 - aspartate, 67
 - atropine, 67
 - carbachol, 67
 - glutamate, 67
 - haloperidol, 67
 - intracranial injection, 67
 - lidocaine, 67
 - oculomotor nucleus, 67
 - propranolol, 67
 - tolazocine, 67
- Phosphodiesterase**
 - adenylate cyclase, 719
 - norepinephrine, 719
 - receptors, 719
 - stress, 719
 - subsensitivity, 719
- Phospholipid**
 - enzymes, 701
 - fat cell, 701
 - lipolysis, 701
 - theophylline, 701
- Physical dependence**
 - adjunctive behavior, 405
 - t-butanol, 633
 - drinking, 633
 - drug preference, 405
 - ethanol, 633, 733
 - hypothermia, 575
 - intraperitoneal infusion, 689
 - jumping, 575
 - locomotor activity, 361
 - morphine, 361, 575, 779
 - morphine substitution, 689
 - naloxone, 361, 575, 779
 - narcotic antagonist analgesic, 689
 - neurotransmitters, 733
 - phenobarbital, 405, 595
 - regional differences, 733
 - schedule-induced behavior, 405, 633
 - taste aversion, 779
 - tolerance, 361
 - UCS pre-exposure, 779
 - withdrawal, 361, 405
- Physostigmine**
 - amnesia, 321
 - cholinergic mechanisms, 321
 - memory, 321
 - scopotamine, 321
- Picrotoxin**
 - GABA, 613
 - hippocampus, 613
 - ketamine, 27
 - memory consolidation, 613
 - metrazol, 27
 - seizures, 27
 - status pathophysiology, 27
- Pimozide**
 - autoshaping, 543
 - classical-operant transfer, 101
 - discrimination learning, 101
 - dopamine, 101, 201
 - extinction, 201, 543
 - haloperidol, 543
 - Pavlovian conditioning, 543
 - receptors, 201
 - stimulation, 543
 - two-process learning theory, 101
 - water reinforcement, 201
- Pineal gland**
 - ethanol, 143
 - melatonin, 143
- Pituitary-adrenal system**
 - approach-avoidance conflict, 447
 - caloric intake, 447
 - consummatory behavior, 447
 - iron deficiency, 447
 - taste aversion, 447
- Plasma catecholamines**
 - glucose, 517
 - glycerol, 517
 - insulin, 517
 - obesity, 517
 - phenoxybenzamine, 517
 - stress, 517
 - sympatho-adrenal system, 517
 - thermogenesis, 517
 - Zucker rat, 517
- Pneumatic syringe**
 - drug self-administration, 573
- Polyethylene glycol**
 - angiotensin, 549
 - 2-deoxyglucose, 549
 - drinking, 549
 - eating, 549
 - insulin, 549
 - opiates, 549
 - opiate antagonists, 549
 - tail-pinch, 549
- POMS**
 - abuse liability, 159
 - amphetamine, 159
 - drug preference, 159
 - human, 159
 - subjective effects, 159
- Portocaval anastomosis**
 - ambulation, 259
 - 5-hydroxyindole acetic acid, 259
 - non-esterified fatty acid, 259
 - serotonin, 259
- Practolol**
 - blood pressure, 313
 - cardiac output, 313

- dobutamine, 313
- heart rate, 313
- left ventricular dP/dt, 313
- stress, 313
- Predatory behavior
 - benzodiazepine derivative modification, s43
- Preference
 - acetaldehyde, 107
 - aldehyde dehydrogenase, 107
 - drinking, 107
 - ethanol, 107
 - genetics, 107
- Prenatal
 - critical periods, 57
 - ethanol, 57
 - fetal alcohol syndrome, 57
 - sensorimotor development, 57
 - viability, 57
- Prepyriform cortex
 - amygdala, 397
 - cocaine, 397
 - kindling, 397
 - lidocaine, 397
 - olfactory bulb, 397
 - seizures, 397
- Primate
 - amphetamine, 345
 - haloperidol, 345
 - reversal learning, 345
- Proline
 - N-acetyl-L-glutamate, 919
 - amnesia, 919
 - chicken, 919
 - glutamate, 919
- Propranolol
 - aspartate, 67
 - atropine, 67
 - carbachol, 67
 - glutamate, 67
 - haloperidol, 67
 - intracranial injection, 67
 - lidocaine, 67
 - oculomotor nucleus, 67
 - phentolamine, 67
 - tolazocine, 67
- Protein
 - amphetamine, 539
 - anorexia, 539
 - behavioral inhibition, 455
 - caloric intake, 539
 - carbohydrate, 539
 - dendrites, 455
 - dietary self-selection, 539
 - DNA, 455
 - fat, 539
 - learning, 455
- Purines
 - Lesch-Nyhan syndrome, 827
 - methylxanthines, 827
 - self-injury, 827
- Pyrazines
 - aging, 787
 - multidimensional scaling, 787
 - odor, 787
- Pyriithiamine
 - deficiency, 153
 - string test, 153
 - thiamine, 153
- Quipazine
 - behavioral activation, 831
 - development, 831
 - mouthng behavior, 831
- neonatal behavior, 831
- serotonin, 831
- Rabbit
 - amygdala central nucleus, 497
 - heart rate conditioning, 497
 - opiates, 497
 - receptors, 497
- Raphe model
 - chicken, 463
 - serotonin, 463
 - tonic immobility, 463
 - tryptophan, 463
- Raphe nucleus
 - abnormal behavior, 89
 - analgesia, 11
 - p-chlorophenylalanine, 11, 89
 - circling behavior, 625
 - 2,5-dimethoxy-4-methylamphetamine, 89
 - dopamine, 625
 - pGlu⁶(SP₆₋₁₁), 11
 - head-twitch, 89
 - 6-hydroxydopamine, 625
 - lesions, 11, 89
 - locomotion, 89
 - LSD, 89
 - mescaline, 89
 - methysergide, 89
 - morphine, 625
 - serotonin, 11, 89, 625
 - species differences, 11
 - stimulation and mouse-killing, s25
 - substance P, 11
- Reactivity
 - dietary tryptophan deprivation, s19
- Receptors
 - acrylamide, 527, 533
 - adenylate cyclase, 719
 - 4-alkyl-2,5-dimethoxyamphetamines, 287
 - 4-alkyl-2,5-dimethoxyphenyl-isopropylamines, 287
 - amygdala central nucleus, 497
 - analgesia, 75
 - apomorphine, 753
 - benzodiazepine, 487, 693
 - B-carbolines, 693
 - catatonia, 75
 - cross-tolerance, 75
 - discriminative stimulus, 287
 - DOET, 287
 - DOM, 287
 - dopamine, 201, 533, 693, 753
 - endogenous ligand, 693
 - extinction, 201
 - harmaline, 693
 - heart rate conditioning, 497
 - irazepine, 487
 - kenazepine, 487
 - LAAM, 753
 - 5-methoxy-N,N-dimethyltryptamine, 287
 - neurotransmitters, 527, 533
 - norepinephrine, 719
 - opiates, 75, 497, 753
 - pentylene-tetrazol, 487
 - phosphodiesterase, 719
 - pimozide, 201
 - rabbit, 497
 - serotonin, 287, 693
 - specificity, 693
 - stereotypy, 753
 - stress, 719
 - subsensitivity, 719
 - tolerance, 75
 - water reinforcement, 201
- Refractory period
 - copulation, 251
 - endorphin, 251

- naloxone, 251
- sexual reflexes, 251
- Regional cerebral blood flow**
 - ACTH/MSH, 845
 - blood-brain barrier, 845
 - ORG-2766, 845
 - permeability, 845
- Regional differences**
 - ethanol, 733
 - MHPG, 729
 - neurotransmitters, 733
 - norepinephrine, 729
 - physical dependence, 733
 - stress, 729
- Reinforcement thresholds**
 - naloxone, 247
 - self-stimulation, 247
- REM sleep**
 - bromocriptine, 371
 - phenoxybenzamine, 371
- Renin**
 - blood pressure, 895
 - decarboxylase inhibitors, 895
 - heart rate, 895
 - serotonin, 895
 - temperature, 895
- Renin-angiotensin system**
 - dopamine, 385
 - drinking, 385
 - 5-hydroxytryptophan, 385
- Reproduction**
 - methadone, 561
 - naltrexone, 561
 - opiates, 561
 - sexual behavior, 561
- Reserpine**
 - lordosis, 707
 - monoamines, 707
 - spinal cord, 707
- Reticular formation**
 - amygdala, 169
 - cataplexy, 169
 - caudate nucleus, 169
 - haloperidol, 169
 - morphine, 169
- Reversal learning**
 - amphetamine, 345
 - haloperidol, 345
 - primate, 345
- Rotation**
 - anticonvulsants, 507
 - seizures, 507
- Runway behavior**
 - anorectics, 799
 - anorexia, 799
 - eating, 799
- Satiety**
 - bombesin, 149
 - eating, 149
 - glucose, 149
 - neurotensin, 149
 - tail pinch, 149
- Schedule-controlled behavior**
 - abstinence, 393
 - drug discrimination, 213
 - LAAM, 393
 - monkey, 213
 - morphine, 393
 - phencyclidine, 213
 - phencyclidine analogues, 213
- Schedule-induced behavior**
 - adjunctive behavior, 405
 - t-butanol, 633
 - drinking, 633
 - drug preference, 405
 - ethanol, 633
 - phenobarbital, 405
 - physical dependence, 405, 633
 - withdrawal, 405
- Schedule induced polydipsia**
 - body weight level, 857
 - ethanol, 857
 - sex differences, 857
 - strain differences, 857
- Scopolamine**
 - amnesia, 321
 - amphetamine, 121
 - anticholinergic, 1
 - avoidance behavior, 121
 - chicken, 669
 - p-chlorophenylalanine, 669
 - cholinergic mechanisms, 321
 - CS modality, 121
 - genetics, 121
 - memory, 321
 - passive avoidance, 669
 - physostigmine, 321
 - skin resistance, 1
- Secobarbital**
 - chlorpromazine, 353
 - ethanol, 353
 - human, 353
 - social interaction, 353
 - speech, 353
 - subjective reports, 353
- Seizure susceptibility**
 - brain weight, 409
 - cocaine, 409
- Seizures**
 - amygdala, 397
 - anticonvulsants, 507
 - cocaine, 397
 - hypoxanthine, 589
 - inosine, 589
 - ketamine, 27
 - kindling, 397
 - kynurenine, 589
 - lidocaine, 397
 - metrazol, 27
 - nicotinamide, 589
 - olfactory bulb, 397
 - pentylentetrazol, 589
 - picROTOXIN, 27
 - prepyriform cortex, 397
 - rotation, 507
 - status pathophysiology, 27
- Self-injury**
 - Lesch-Nyhan syndrome, 827
 - methylxanthines, 827
 - purines, 827
- Self-stimulation**
 - benzodiazepines, 219
 - conflict situation, 219
 - hypothalamus, 219
 - morphine, 325
 - naloxone, 247, 325
 - reinforcement thresholds, 247
 - substantia nigra, 325
 - ventral tegmentum, 325
- Sensorimotor development**
 - critical periods, 57
 - ethanol, 57
 - fetal alcohol syndrome, 57
 - prenatal, 57
 - viability, 57
- Septum**
 - acetylcholine, 35

aggression, 35
 defensiveness, 35
 dopamine, 35
 glutamate, 35
 hyperreactivity, 35
 norepinephrine, 35

Serotonin
 abnormal behavior, 89
 4-alkyl-2,5-dimethoxyamphetamines, 287
 4-alkyl-2,5-dimethoxyphenyl-isopropylamines, 287
 ambulation, 259
 analgesia, 11
 behavioral activation, 831
 behavioral reactivity, 815
 benzodiazepine, 693
 blood pressure, 895
 brain levels and tryptophan deprivation, s19
 B-carbolines, 693
 castration, 293
 catalepsy, 469
 chicken, 463, 469
 p-chlorophenylalanine, 11, 89, 293, 910
 circling behavior, 625
 conflict behavior, 617
 decarboxylase inhibitors, 889, 895
 development, 831
 5,7-dihydroxytryptamine, 915
 2,5-dimethoxy-4-methylamphetamine, 89
 discriminative stimulus, 287
 DOET, 287
 DOM, 287, 595, 617
 dopamine, 469, 625, 693
 drinking, 889
 endogenous ligand, 693
 ethanol, 293
 pGlu⁶(SP₆₋₁₁), 11
 hallucinogens, 595, 915
 harmaline, 693
 head twitch, 89
 heart rate, 895
 hibernation, 773
 hippocampus, 815
 6-hydroxydopamine, 625
 5-hydroxyindoleacetic acid, 259
 5-hydroxytryptophan, 889
 hypothalamus, 910
 lesions, 11, 89
 LH, 293
 locomotion, 89
 LSD, 89, 595, 617
 MAO, 773
 medial forebrain bundle, 915
 mescaline, 89, 595
 methaqualone, 617
 5-methoxy-N,N-dimethyltryptamine, 287
 methysergide, 89
 morphine, 625
 mouthing behavior, 831
 muscarinic, 693
 neonatal exposure, 831
 non-esterified fatty acid, 259
 norepinephrine, 815
 operant behavior, 595, 915
 pentobarbital, 617
 phenobarbital, 405, 595
 portocaval anastomosis, 259
 quipazine, 831
 raphe model, 463
 raphe nucleus, 11, 89, 625
 receptors, 287, 693
 renin, 895
 species differences, 11
 specificity, 693
 steroidogenesis, 910
 substance P, 11

temperature, 895
 tonic immobility, 463, 469
 tryptophan, 463, 469

Sex differences
 activity, 5
 amphetamine, 5, 17
 apomorphine, 17
 body weight level, 857
 development, 5
 dopamine, 5
 ethanol, 857
 gonadectomy, 17
 6-hydroxydopamine, 5
 locomotor activity, 17
 schedule induced polydipsia, 857
 stereotyped behavior, 17
 strain differences, 857

Sexual behavior
 lordosis, 745
 methadone, 561
 naloxone, 881
 naltrexone, 561, 881
 opiates, 561, 881
 reproduction, 561
 Δ⁹-tetrahydrocannabinol, 745
 ultrasounds, 745

Sexual dimorphism
 aggression in rats, s89

Sexual reflexes
 copulation, 251
 endorphin, 251
 naloxone, 251
 refractory period, 251

Shock-induced aggression
 cyclic AMP, s7
 cyclic GMP, s7
 GABAergic system involvement, s13

Shock thresholds
 aggression, 175
 nicotine, 175

Sidman avoidance
 antipsychotic drugs, 181
 discriminated avoidance, 181

Silicone delivery system
 binge vs continuous drug regimen, 207
 ethanol, 207
 intoxication, 207
 withdrawal, 207

Skeletal growth
 activity, 443
 eating, 443
 food restriction, 443
 hypothyroidism, 443

Skin resistance
 anticholinergic, 1
 scopolamine, 1

Sleep
 hypnotics, 811
 light-dark cycle, 811

Sleep time
 cerebellum, 227
 electrophysiology, 227
 ethanol, 227
 genetics, 227
 hippocampus, 227

Social crowding
 endorphine, 299
 naloxone, 299
 taste aversion, 299

Social interaction
 chlorpromazine, 353
 ethanol, 353
 secobarbital, 353
 speech, 353
 subjective reports, 353

- Spatial aversion
 - drug reinforcement, 263
 - ethanol, 263
- Species differences
 - analgesia, 11
 - axonal transport, 863
 - p-chlorophenylalanine, 11
 - colchicine, 863
 - pGlu⁶⁻¹¹(SP₆₋₁₁), 11
 - lesions, 11
 - memory, 863
 - raphe nucleus, 11
 - serotonin, 11
 - substance P, 11
 - tubulin, 863
 - uptake, 863
- Specificity
 - benzodiazepines, 693
 - B-carbolines, 693
 - dopamine, 693
 - endogenous ligand, 693
 - harmaline, 693
 - muscarinic, 693
 - receptors, 693
 - serotonin, 693
- Speech
 - chlorpromazine, 353
 - ethanol, 353
 - human, 353
 - secobarbital, 353
 - social interaction, 353
 - subjective reports, 353
- Speed drugs
 - induced psychopathology, s109
- Spinal cord
 - lordosis, 707
 - monoamines, 707
 - reserpine, 707
- Status pathophysiology
 - ketamine, 27
 - metrazol, 27
 - picrotoxin, 27
 - seizures, 27
- Stereotyped behavior
 - amphetamine, 17
 - apomorphine, 17, 493, 753
 - caudate nucleus, 273
 - combined specific therapy, 273
 - determinant structure, 273
 - diazepam, 273
 - dopamine, 753
 - food deprivation, 493
 - GABA, 273
 - gonadectomy, 17
 - haloperidol, 273
 - LAAM, 753
 - lithium, 273
 - locomotor activity, 17
 - opiates, 753
 - pharmacokinetics, 493
 - receptors, 753
 - sex differences, 17
- Steroidogenesis
 - p-chlorophenylalanine, 910
 - hypothalamus, 910
 - serotonin, 910
- Stimulation
 - autoshaping, 543
 - extinction, 543
 - haloperidol, 543
 - Pavlovian conditioning, 543
 - pimozide, 543
- Strain differences
 - body weight level, 857
 - ethanol, 857
 - schedule induced polydipsia, 857
 - sex differences, 857
- Stress
 - adenylate cyclase, 719
 - blood pressure, 313
 - cardiac output, 313
 - corticosterone, 749
 - diazepam, 333
 - dobutamine, 313
 - endorphins, 113
 - glucose, 517
 - glycerol, 517
 - heart rate, 313
 - histamine, 333
 - insulin, 517
 - learned helplessness, 823
 - left ventricular dP/dt, 313
 - MHPG, 729
 - naloxone, 113, 749
 - norepinephrine, 719, 729
 - nortriptyline, 823
 - obesity, 517
 - phenoxybenzamine, 517
 - phosphodiesterase, 719
 - plasma catecholamines, 517
 - practolol, 313
 - receptors, 719
 - regional differences, 729
 - subsensitivity, 719
 - sympatho-adrenal system, 517
 - thermogenesis, 517
 - Zucker rat, 517
- Stress-induced analgesia
 - cross-tolerance, 677
 - inescapable shock, 677
 - learned helplessness, 677
 - morphine, 677
- String test
 - deficiency, 153
 - pyrithiamine, 153
 - thiamine, 153
- Strychnine
 - caudate nucleus, 193
 - evoked potentials, 193
 - lateral geniculate, 193
 - occipital cortex, 193
 - passive avoidance, 193
- Subjective effects
 - abuse liability, 159
 - amphetamine, 159
 - chlorpromazine, 353
 - drug preference, 159
 - ethanol, 353
 - human, 159, 353
 - POMS, 159
 - secobarbital, 353
 - social interaction, 353
 - speech, 353
- Submissive behavior
 - dopamine mediation in monkeys, s95
- Subsensitivity
 - adenylate cyclase, 719
 - norepinephrine, 719
 - phosphodiesterase, 719
 - receptors, 719
 - stress, 719
- Substance P
 - analgesia, 11
 - p-chlorophenylalanine, 11
 - pGlu⁶⁻¹¹(SP₆₋₁₁), 11
 - lesions, 11
 - raphe nucleus, 11
 - serotonin, 11
 - species differences, 11
- Substantia nigra
 - morphine, 325
 - naloxone, 325

- self-stimulation, 325
- ventral tegmentum, 325
- Sympatho-adrenal system
 - glucose, 517
 - glycerol, 517
 - insulin, 517
 - obesity, 517
 - phenoxybenzamine, 517
 - plasma catecholamines, 517
 - stress, 517
 - thermogenesis, 517
 - Zucker rat, 517
- Tail flick
 - analgesia, 133, 139
 - morphine, 133, 139
 - tolerance, 133, 139
- Tail pinch
 - angiotensin, 549
 - bombesin, 149
 - 2-deoxyglucose, 549
 - drinking, 549
 - eating, 149, 549
 - glucose, 149
 - insulin, 549
 - neurotensin, 149
 - opiates, 549
 - opiate antagonists, 549
 - polyethylene glycol, 549
 - satiety, 149
- Taste aversion
 - approach-avoidance conflict, 447
 - caloric intake, 447
 - cathinone, 907
 - consummatory behavior, 447
 - dopamine, 85
 - endorphin, 299
 - 6-hydroxydopamine, 85
 - iron deficiency, 447
 - Khat, 907
 - lithium chloride, 85
 - methylamphetamine, 85
 - morphine, 779
 - naloxone, 299, 799
 - physical dependence, 779
 - pituitary-adrenal system, 447
 - social crowding, 299
 - UCS pre-exposure, 779
- Temperature
 - blood pressure, 895
 - decarboxylase inhibitors, 895
 - heart rate, 895
 - renin, 895
 - serotonin, 895
- Temperature-sensitive mutants
 - cAMP, 603
 - cyclic nucleotide phosphodiesterase, 603
 - Drosophila melanogaster*, 603
 - learning, 603
 - locomotor activity, 603
 - x-chromosome, 603
- Territorial aggression
 - DU 27725 and anti-aggressive properties, 361
- Δ^9 -Tetrahydrocannabinol
 - lordosis, 745
 - sexual behavior, 745
 - ultrasounds, 745
- Tetrahydroisoquinolines
 - avoidance behavior, 639
 - intraventricular injections, 639
 - locomotor activity, 639
- Thebaine
 - codeine, 805
 - drug self-administration, 805
 - naloxone, 805
 - operant behavior, 805
- Theophylline
 - enzymes, 701
 - fat cell, 701
 - lipolysis, 701
 - phospholipid, 701
- Thermogenesis
 - glucose, 517
 - glycerol, 517
 - insulin, 517
 - obesity, 517
 - phenoxybenzamine, 517
 - plasma catecholamines, 517
 - stress, 517
 - sympatho-adrenal system, 517
 - Zucker rat, 517
- Thermoregulation
 - behavioral regulation, 653
 - body weight, 653
 - eating, 653
 - methadone, 653
 - perinatal exposure, 653
- Thiamine
 - deficiency, 153
 - pyrithiamine, 153
 - string test, 153
- Tissue tolerance
 - ethanol, 165
 - genetics, 165
 - metabolic tolerance, 165
 - tolerance, 165
- Tolazocine
 - aspartate, 67
 - atropine, 67
 - carbachol, 67
 - glutamate, 67
 - haloperidol, 67
 - intracranial injection, 67
 - lidocaine, 67
 - oculomotor nucleus, 67
 - phentolamine, 67
 - propranolol, 67
- Tolerance
 - amphetamine, 661
 - analgesia, 75, 133, 139, 757
 - anorexia, 481
 - body weight regulation, 661
 - catatonia, 75
 - caudate nucleus, 481
 - cross-tolerance, 75
 - dopamine, 481
 - eating, 661
 - environmental stimuli, 757
 - ethanol, 165
 - fenfluramine, 661
 - genetics, 165
 - hot plate, 757
 - locomotor activity, 361
 - metabolic tolerance, 165
 - methamphetamine, 481
 - morphine, 133, 139, 361, 757
 - naloxone, 361
 - opiates, 75
 - physical dependence, 361
 - receptors, 75
 - tail flick, 133, 139
 - tissue tolerance, 165
 - withdrawal, 361
- Tonic immobility
 - cataplexy, 469
 - chicken, 463, 469
 - dopamine, 469
 - raphe model, 463

- serotonin, 463, 469
- tryptophan, 463, 469
- TRH
 - activity, 901
 - cardiovascular effects, 901
 - goat, 901
 - intraventricular administration, 901
- Tryptophan
 - catalepsy, 469
 - chicken, 463, 469
 - dopamine, 469
 - raphe model, 463
 - serotonin, 463, 469
 - tonic immobility, 463, 469
- Tryptophan deprivation
 - brain serotonin levels, s19
 - mouse-killing, s19
 - reactivity, s19
- Tubulin
 - axonal transport, 863
 - colchicine, 863
 - memory, 863
 - species differences, 863
 - uptake, 863
- Two-process learning theory
 - classical-operant transfer, 101
 - discrimination learning, 101
 - dopamine, 101
 - pimozide, 101
- UCS pre-exposure
 - morphine, 779
 - naloxone, 779
 - physical dependence, 779
 - taste aversion, 779
- Ultrasounds
 - lordosis, 745
 - sexual behavior, 745
 - Δ^9 -tetrahydrocannabinol, 745
- Unit activity
 - amphetamine, 49
 - amygdala, 49
 - clozapine, 49
 - haloperidol, 49
- Uptake
 - axonal transport, 863
 - colchicine, 863
 - memory, 863
 - species differences, 863
 - tubulin, 863
- Vaginal stimulation
 - antinociception, 631
 - naloxone, 631
- Ventral tegmentum
 - morphine, 325
 - naloxone, 325
 - self-stimulation, 325
 - substantia nigra, 325
- Ventromedial hypothalamus
 - dietary quinine, 283
 - drug metabolism, 283
 - lesions, 283
- Viability
 - critical periods, 57
 - ethanol, 57
 - fetal alcohol syndrome, 57
 - prenatal, 57
 - sensorimotor development, 57
- Water deprivation
 - cat, 419
 - drinking, 419
 - eating, 419
 - food deprivation, 419
 - naloxone, 419
- Water reinforcement
 - dopamine, 201
 - extinction, 201
 - pimozide, 201
 - receptors, 201
- Withdrawal
 - adjunctive behavior, 405
 - binge vs continuous drug regimen, 207
 - drug preference, 405
 - ethanol, 207
 - intoxication, 207
 - locomotor activity, 361
 - morphine, 361
 - naloxone, 361
 - phenobarbital, 405, 595
 - physical dependence, 361, 405
 - schedule-induced behavior, 405
 - silicone delivery system, 207
 - tolerance, 361
- X-chromosome
 - cAMP, 603
 - cyclic nucleotide phospho-diesterase, 603
 - Drosophila melanogaster*, 603
 - learning, 603
 - locomotor activity, 603
 - temperature-sensitive mutants, 603
- Zucker rat
 - glucose, 517
 - glycerol, 517
 - insulin, 517
 - obesity, 517
 - phenoxybenzamine, 517
 - plasma catecholamines, 517
 - stress, 517
 - sympatho-adrenal system, 517
 - thermogenesis, 517

AUTHOR INDEX

- ABRAHAM, L. D., 433
ADVOKAT, C., 133, 139
AGRAWAL, A. K., 527, 533
AHRENDSSEN, K., 405
AIGNER, T. G., 481
ALBERT, D. J., 35, 67
ALBERTI, M. H., 863
ALIEV, M. N., 273
ALLOWAY, K. D., 49
ALTSHULER, H. L., 97
AMMASSARI-TEULE, M., 741
APFELBACH, R., s43
APPEL, JAMES B., 339
APPLEBAUM, E., 97
AYLIFFE, S. J., 631
- BAETTIG, K., 175, 857
BAKER, H. F., 345, 849
BALSTER, R. L., 213
BAR, P. R., 305
BARCHAS, J. D., 677
BARCLAY, L. L., 153
BARDO, M. T., 757
BARNEY, C. C., 889, 895
BASHORE, T. R., 49
BEARDSLEY, P. M., 871
BEATTY, W. W., 17
BEDFORD, J. A., 81, 725
BELESLIN, D. B., s29
BENINGER, R. J., 101
BENNETT, E. L., 863
BERGMAN, J., 423
BERNTSON, G. G., 113
BIGELOW, G. E., 353
BIRNKRANDT, D., 41
BITTNER, S. E., 481
BLASS, J. P., 153
BLOXAM, D. L., 259
BLUM, K., 835
BODNAR, R. J., 579, 645
BONDY, S. C., 527, 533
BORDASH, G. D., 463, 469
BORBE, H. O., 693
BORNE, R. F., 81
BRADY, K. T., 213
BRADY, L. S., 361
BREESE, G. R., 293
BRETT, L. P., 447
BRIGGS, A. H., 835
BRODIE, M., 371
BROEKKAMP, C. L., 169
BROWN, D. F., 283
BRUST-CARMONA, H., 193
BURRIGHT, R. G., 409, 877
- CAREY, M. P., 569
CARNEY, J. M., 683
CARROLL, M. E., 415
CHAMPNEY, T. C., 113
CHAPIN, R. E., 293
CHERKIN, A., 919
COLLINS, A. C., 57
COMAI, K., 517
COMMISSARIS, R. L., 595, 617, 915
CONCANNON, J. T., 5
CONNOR, T. M., 385
CORSO, P., JR., 463, 469
COTTAM, G., 725
CRANE, P., 207
CROW, T. J., 849
CUNNINGHAM, C. L., 263
CURZON, G., 259
- DALLMAN, P. R., 447
DALTON, T. K., 733
DAVIS, J. L., 919
DAVIS, J. M., s95
DAVIS, L. G., 839
DEBOLD, J. F., s89
DELALLO, L., 835
DE LA MORA, P., 193
DELINI-STULA, A., s33
DEMIRIAN, L., 41
DESSI-FULGHERI, F., 911
DEUTSCH, J. A., 321
DLOHOŽKOVA, N., s47
DOLINSKY, Z., 877
DONOVICK, P. J., 409, 877
DOOT, D. L., 287
DRISCOLL, P., 175
DRUGAN, R. C., 677
DUNSTAN, R., 169
DUNWIDDIE, T., 227
DURIASZ, H., 11
- EICHELMAN, B., s7
ELLIOTT, C., 725
ELLISON, G., 207
ELSOHLY, H. N., 725
ELSTON, S. F., 835
ENNS, M. P., 569
ERIKKSON, L., 901
ESPOSITO, R. U., 247
- FALK, J. L., 405
FANELLI, R. J., 409
FARABOLLINI, F., 911
FEHSKE, K. J., 693
FIGLER, M. H., s79
- FINK, E., 877
FISH, B. S., 57
FLAGG, H. C., 251
FLOOD, J. F., 863
FLOODY, O. R., 745
FLORCZYK, A. P., 255
FOLEY, T. L., 549
FOLTIN, R. W., 85, 907
FOSTER, J. A., 419
FREED, W. J., 223
FREEDMAN, R., 227
FREGLY, M. J., 385, 889, 895
FRENK, H., 419
- GAGE, F. H., 815
GAJEWSKA, S., 11
GALLAGHER, M., 497
GARDNER, E. L., 325
GERBER, G. J., 201
GIBSON, G. E., 153
GISPEN, W. H., 305
GLENNON, R. A., 287
GLICK, S. D., 507
GOLDMAN, H., 845
GOLOVCHINSKY, V., 27
GOMITA, Y., 219
GORDIN, A., 901
GRANT, K. A., 633
GRAU, J. W., 677
GRECKSCH, G., 613
GREENLEAF, J. E., 889
GRIFFITHS, R. R., 353
GRIGNOLO, A., 313
GRATTON, I., 41
GUNION, M. W., 283
- HALPERIN, J. M., 811
HAMMER, R. P., JR., 455
HARTEL, C. R., 805
HAYSTEAD, T. A. J., 345, 849
HEGSTRAND, L. R., s7
HENDRICKS, C., 397
HERZ, A., 75
HEWITT, M., 919
HILL, M., 419
HILL, R. G., 631
HO, L., 539
HOFFER, B., 227
HOLOHEAN, A. M., 339
HOLLOWAY, F. A., 683
HOLTZMAN, S. G., 241, 361
HORSBURGH, R. J., 1
HOWES, J. F., 689
HUGHES, R. A., 757

HUNT, W. A., 733

INOUE, K., 107
 IORIO, L. C., 811
 ISAACSON, R. L., 305

JACOBS, W. J., 779
 JANICKI, P., 11
 JOHANSON, C. E., 159, 423
 JOLICOEUR, F. B., 235
 JONES, S. M., 299

KAMYSHEV, N. G., 603
 KANAREK, R. B., 539
 KANTAK, K. M., s7
 KANTAMANENI, B. D., 259
 KAPP, B. S., 497
 KARLI, P., s3
 KEMPF, E., s13, s19
 KIKTA, D. C., 385, 889, 895
 KIRLANGITIS, J., 753
 KOHNO, Y., 729
 KORDOWER, J. H., 645
 KORNETSKY, C., 247
 KOSAR, E., s47
 KOSTOWSKI, W., s25
 KOW, L.-M., 707
 KRŠIAK, M., s47
 KRYZHANOVSKY, G. N., 273
 KURIBARA, H., 181

LANGLEY, A. E., 753
 LAPIN, I. P., 589
 LEFFINGWELL, J. C., 787
 LEHMAN, T., 753
 LEVIN, B. E., 517
 LEVINE, A. S., 149
 LEVINE, S., 447
 LEVITSKY, D. A., 661
 LIEBSON, I., 353
 LIGHT, K. C., 313
 LINDROS, K. O., 107, 377
 LLOYD, K. G., 169
 LLOYD, H. G. E., 827
 LoLORDO, V. M., 779
 LUPO DI PRISCO, CO., 911
 LUPOLI, J., 661
 LYNESS, W. H., 595, 617, 915

McCLEARN, G., 227
 McDONALD, A. C., 543
 McINTOSH, H., 839
 McMURRAY, T., s7
 McNALL, C. L., 497

MADDEN, J., IV, 677
 MAIER, S. F., 677
 MAKOWSKI, E. C., 639
 MANDEL, P., s13
 MARDONES, J., 165
 MARTIN, J. R., 857
 MAŠEK, K., s47
 MATTE, A. C., s85
 MATTHIES, H., 613
 MATTINGLY, B. A., 669
 MATTSON, M., 487
 MAZURKIEWICZ-KWILECKI,
 I. M., 333
 MEADE, R. G., 539
 MEISCH, R. A., 871
 MERKEL, A. D., 235
 MERRIGAN, K. P., 579
 MÉSZAROS, J., 11
 MICZEK, K. A., s1, s89, s103
 MILLER, D., 811

MINTZ, M., 27
 MINTZ, R., 235
 MITTLER, J. C., 749
 MIYOSHI, Y., 701
 MODROW, H. E., 683
 MOGILNICKA, E., 129
 MOKLER, D. J., 915
 MONTGOMERY, A., 475
 MOORE, K. E., 595, 915
 MORLEY, J. E., 149
 MORRISON, M., 419
 MOSS, D. E., 321
 MUELLER, R. A., 293
 MÜLLER, W. E., 693
 MURPHY, M. R., 561
 MURPHY, S., 845
 MYSLOBODSKY, M. S., 27

NAGAI, K., 701
 NAGASAKI, N., 729
 NAIL, G. L., 81
 NAKAGAWA, R., 729
 NAKANO, S., 493
 NANZ, C., 693
 NATELSON, B. H., 749
 NAZZARO, J. M., 325
 NELSON, J. L., 549
 NEUSCHAFER, S. J., 419
 NIKOLETSEAS, M. M., 443
 NOBLE, R. G., 881
 NODA, Y., 729
 NOVIN, D., 283

OBRIST, P. A., 313
 OGAWA, N., 493
 OKUDA, H., 701
 OLIVERIO, A., 741
 OLIVIER, B., s61
 ORDOÑEZ, L. A., 639
 OSTROWSKI, N. L., 549, 881

PADEN, C. M., 707
 PALFAI, T., 713
 PAUL, S. M., 487
 PAULUCCI, T. S., 113
 PASCOE, J. P., 497
 PEEKE, H. V. S., s79
 PERRY, W., 247
 PETERS, R. H., 283
 PFAFF, D. W., 707
 PHILLIPS, A. G., 101, 543
 PIERSON, R. N., JR., 41
 PILCHER, C. W. T., 299
 POLLACK, J., 41
 POPOVA, N. K., 773
 POSHIVALOV, V. P., s53
 PRZEWLOCKA, B., 129
 PUCITOWSKI, O., s25
 PUGLISI-ALLEGRA, S., s13

QUINTANILLA, M. E., 165

RADULOVACKI, M., 371
 RANK, S. A., 57
 REBEC, G. V., 49
 RECH, R. H., 595, 617, 915
 REID, L. D., 549, 881
 REKER, D., 839
 RENZI, P., 741
 RICE, K. C., 487
 RIDLEY, R. M., 345, 849
 RILEY, A. L., 779

RISTINE, L. A., 831
 RITZ, A., 409

RITZMANN, R. F., 575
 ROGERS, J. B., 321
 ROMMELSPACHER, H., 693
 ROSS, J. A., 569
 ROWLAND, N., 549
 RUDEEN, P. K., 143
 RUDELL, R. L., 415
 RUSI, M., 107

SACHS, B. D., 251
 SALOME, R. R., 321
 SAMANIN, R., 799
 SAMARDŽIĆ, R., s29
 SAMSON, H. H., 633
 SANSONE, M., 741
 SANTI, P. A., 415
 SATINDER, K. P., 121
 SAVAGEAU, M. M., 17
 SAVVATEEVA, E. V., 603
 SCHAEFER, G. J., 241
 SCHECHTER, M. D., 5, 23, 269
 SCHIFFMAN, S. S., 787
 SCHIØRRING, E., s109
 SCHLEMMER, R. F., JR., s95
 SCHLISSERMAN, S., s103
 SCHONFELD, A. R., 507
 SCHULZ, R., 75
 SCHURIG, J. E., 255
 SCHUSTER, C. R., 85, 117, 805, 907
 SCHWERTNER, H., 835
 SEEGER, T. F., 325
 SEIDEN, L. S., 85, 117, 481
 SETH, P. K., 527
 SHIPPENBERG, T. S., 97
 SIMLER, S., s13
 SINCLAIR, J. D., 377
 SING, J., 201
 SINGHAL, R. L., 823
 SKOLNICK, P., 487
 SLATER, P., 625
 SMITH, D. F., 439
 SORENSEN, S., 227
 SPEAR, L. P., 831
 SPIRDUSO, W. W., 433
 SPRINGER, J. E., 815
 SQUIBB, R. E., 527
 STAUGAITIS, S., 207
 STEFANOVIĆ-DENIC, K., s29
 STEINFELS, G. F., 393
 STITZER, M. L., 353
 STONE, E. A., 719
 STONE, T. W., 827
 STRIPLING, J. S., 397
 STRUPP, B. J., 661
 ŠULCOVA, A., s47
 SULLIVAN, A. C., 517
 SYMCHOWICZ, B., 409
 SYMMES, S. K., 143
 SZRENIAWSKI, Z., 11

TADOKORO, S., 181
 TAKEDA-HARA, E., 701
 TAMIR, H., 645
 TAMPPIER, L., 165
 TANAKA, M., 729
 TANG, M., 405
 TARCHALSKA, B., 11
 TAPP, W. N., 749
 TELLEZ-VILLAGRA, C., 193
 TELNER, J. I., 823
 THEODOROU, A., 475
 THOMPSON, C. I., 653
 THREATTE, R. M., 385, 889, 895
 THURLBY, P. L., 799
 TILSON, H. A., 527, 533

TOMAŠÍKOVÁ, Z., s47
TRICKLEBANK, M. D., 259
TURLEY, W. A., JR., 745
TURNER, C. E., 725

UEKI, S., 89, 219
UCHIDA, K., 701
UHLENHUTH, E. H., 159
UPHOUSE, L. L., 527

VALCOURT, R. J., 251
VAN MARTHENS, E., 455
VASSOUT, A., s33
VAZQUEZ, F., 193
VERGNES, M., s19
VILLESCAS, R., 455
VOITENKO, N. N., 773

WAGNER, G. C., 85, 117, 481
WALKER, J. M., 113
WALLACE, M. M., 579, 645
WALLNAU, L. B., 463, 469
WANG, J., 41
WALOVITCH, R., 371
WALSH, T. J., 713
WATANABE, H., 493
WAYNER, M. J., 235
WEEKS, J. R., 573
WEINBERG, J., 447
WELLMAN, P. J., 757
WHITE, FRANCIS J., 339
WILKIE, D. M., 543
WILLIAMS, E. F., 487
WILLNER, P., 475
WILSON, J. R., 57
WILSON, M. C., 81, 725

WISE, R. A., 201
WOJCIK, W. J., 371
WOLLERT, U., 693
WOLF, M. D., 433
WOODS, J. H., 805
WOLLEY, J., s103
WÜSTER, M., 75
WYATT, R. J., 223

YAMAMOTO, T., 89
YOSHIMURA, H., s103
YOUNG, G. A., 393
YOUNG, R., 287

ZAGON, I. S., 653
ZELLNER, D. A., 779
ZOLMAN, J. F., 669